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ABSTRACT 
CHIA LI: Modulation of Ventral Periaqueductal Gray Dopamine Neurons 
(Under the direction of Dr. Thomas L. Kash) 
 
Dopamine (DA) neurons within the ventral periaqueductal gray (vPAG) regulate 
reward, as well as negative emotional behaviors that often lead to addiction relapse.  Due 
to the cell-type heterogeneity of the vPAG, little is known about the functional properties 
of these neurons, or how drugs of abuse, such as opioids and alcohol, modulate them.  In 
these studies, transgenic mouse lines were used to evaluate the properties, projection, and 
functional modulation of vPAG DA neurons. Alcohol modulation of synaptic 
transmission was examined; acute alcohol had minimal effects on GABA transmission, 
but resulted in a robust enhancement of glutamatergic transmission onto vPAG dopamine 
neurons, as well as an increase in firing rate of these neurons.  Interestingly, chronic 
intermittent alcohol exposure produced no significant alterations on either inhibitory or 
excitatory synaptic transmission, suggesting that alcohol has both region- and cell-type-
dependent effects on function.  Negative emotional behaviors during withdrawal, a 
critical component of drug addiction, can often lead to relapse, making the study of such 
behaviors relevant and essential.  The kappa opioid receptor (KOR) system has been 
implicated in disruption of affective behaviors including depression, anxiety, and drug 
abuse, some of which are mediated via dopamine signaling.  Previous studies have shown 
that stress-induced dysphoria can augment KOR expression in dopamine-rich brain 
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regions, providing a link between kappa opioid modulation and dopamine signaling.  Due 
to the link between dopamine, drug abuse, and the behavioral relevance of the ventral 
periaqueductal gray (vPAG), this work aimed to elucidate the mechanisms underlying 
opioid modulation of GABAergic inputs onto vPAG DA neurons.  In this study, 
activation of KOR significantly reduced GABAergic inhibition of vPAG DA neurons.  In 
addition, mechanistic investigation suggested that this effect was mediated via pre-
synaptic mechanisms of the G-protein coupled receptor βγ subunit.  Finally, this work 
demonstrated that the vPAG DA neurons are glutamatergic, and project to the bed 
nucleus of stria terminalis (BNST), a part of the extended amygdala that regulates stress-
related behavior.  Using viral tools, the potential of vPAG dopamine neurons in 
modulating behaviors, as well as activity of projection targets were demonstrated.  
Therefore, this work provides insight into the regulation of negative affective behavior 
for potential improvement in treatments for emotional disorders and drug abuse. 
 v 
To my father, 李林峰, and my mother, 劉淑鎂, for their love and support. 
 
感謝你們無私無條件的寵愛、教誨與支持。 
此論文不足彰顯從小至今你們對我的付出，但我對你們的感謝及關愛永無止盡。
 vi 
ACKNOWLEDGEMENTS 
First and foremost, I wish to express my gratitude towards Dr. Thomas Kash for 
his infinite advice, patience, and support.  The training I have received under his 
guidance will undoubtedly benefit me throughout my scientific career.  My committee 
members, Dr. McCarthy, Dr. Hodge, Dr. Johns, and Dr. Criswell, have been very helpful 
offering their time, knowledge, insightful suggestions and guidance through the process 
of this dissertation.  This work would not have been possible without the hard work and 
support from everyone in the Kash lab past and present, especially Nora McCall, Alberto 
Lopez, and Dr. Emily Lowery-Gionta, for advices towards the writing of this dissertation.  
Additional recognition is required for my undergraduate mentor Dr. Rick Bevins, who 
lead me into the world of research and guided me through the early stages of being a 
scientist; and throughout my graduate career, Dr. Darin Knapp has been a good friend, 
and a wonderful mentor.  I would like to thank all my friends and family in Taiwan and 
the United states for their moral support throughout this process.  I especially want to 
thank Brian Mehl for his unwavering support, patience, and love, and for sharing his life 
with me.  The primary funding for this project came from a grant from the National 
Institute on Alcohol Abuse and Alcoholism (AA017668).  The last academic year of my 
graduate program was additionally funded by the UNC Graduate School Dissertation 
Completion Fellowship.  
 
 vii 
TABLE OF CONTENTS 
TABLE OF CONTENTS .............................................................................................. vii 
LIST OF FIGURES ........................................................................................................ ix 
LIST OF ABBREVIATIONS ....................................................................................... xiv 
CHAPTER 1. GENERAL INTRODUCTION ................................................................. 1 
DOPAMINE SIGNALING .......................................................................................... 1 
PERIAQUEDUCTAL GRAY ..................................................................................... 4 
ALCOHOL ................................................................................................................. 7 
KAPPA OPIOID RECEPTORS ................................................................................ 15 
KAPPA OPIOID RECEPTORS AND ALCOHOLISM ............................................. 17 
DISSERTATION ...................................................................................................... 19 
CHAPTER 2. EFFECTS OF ALCOHOL ON VPAG DOPAMINE 
NEURONS.......................................................................................... 22 
INTRODUCTION ..................................................................................................... 22 
MATERIALS AND METHODS ............................................................................... 24 
RESULTS ................................................................................................................. 28 
DISCUSSION ........................................................................................................... 32 
CONCLUSIONS ....................................................................................................... 37 
FIGURES AND TABLES ......................................................................................... 38 
CHAPTER 3. MODULATION OF KAPPA OPIOID RECEPTORS ON 
VPAG DOPAMINE NEURONS ......................................................... 45 
INTRODUCTION ..................................................................................................... 45 
 viii 
MATERIALS AND METHODS ............................................................................... 51 
RESULTS ................................................................................................................. 54 
DISCUSSION ........................................................................................................... 58 
FIGURES AND TABLES ......................................................................................... 63 
CHAPTER 4. VPAG DOPAMINE MODULATION ON PROJECTION 
AREA AND ITS BEHAVIORAL IMPLICATIONS ........................... 71 
INTRODUCTION ..................................................................................................... 71 
MATERIALS AND METHODS ............................................................................... 75 
RESULTS ................................................................................................................. 81 
DISCUSSION ........................................................................................................... 85 
FIGURES AND TABLES ......................................................................................... 90 
CHAPTER 5. GENERAL DISCUSSION .................................................................... 101 
REFERENCES 107 
 ix 
LIST OF FIGURES 
Figure 2.1:  The tyrosine hydroxylase-eGFP transgenic mouse model 
identifies dopamine neurons via fluorescence in the vPAG.  (A) 
Immunohistochemistry can be used to label and verify validity of the 
reporter via (1) tyrosine hydroxylase fluorescence, (2) eGFP 
fluorescence, and the (3) co-localization of eGFP and tyrosine 
hydroxylase in dual-positive cells.  No significant Ih current was 
observed in vPAG DA neurons (B) (1) eGFP and tyrosine 
hydroxylase-positive cells can be visualized under the microscope to 
selectively record from.  Staining showed that the recorded cells 
loaded with (2) neurobiotin via diffusion from the patching pipette, 
are (3) tyrosine hydroxylase-positive. .......................................................................... 38 
Figure 2.2:  The dopamine neurons in the VTA and in the vPAG display 
different electrophysiological membrane properties.  (A) vPAG 
dopamine neurons have significantly lower membrane capacitance (p 
< 0.0001) than VTA dopamine neurons.  (B) vPAG dopamine 
neurons have significantly higher membrane resistance (p < 0.0001) 
than VTA dopamine neurons.  (C), (D) vPAG dopamine neurons 
display little to no hyperpolarization current (Ih) comparing to VTA 
dopamine neurons. ....................................................................................................... 39 
Figure 2.3:  Acute bath-applied alcohol had no effect on mini inhibitory 
post synaptic currents (mIPSCs) in vPAG dopamine neurons.  (A) 
Representative mIPSC traces of baseline control (i) and after 10 
minutes of alcohol wash-on (ii). (B) Acute alcohol had no effect on 
mIPSC frequency. (C) Acute alcohol had no effects on mIPSC 
amplitude. (D) Acute alcohol had no effect on mIPSC decay. (E) 
Acute alcohol had no effect on mIPSC noise. ............................................................... 40 
Figure 2.4:  Acute bath-applied alcohol had no effects on spontaneous 
inhibitory post synaptic current (sIPSC) frequency in vPAG 
dopamine neurons.  Representative sIPSC traces of (A) baseline 
control and (B) after 10 minutes of alcohol wash-on. (C) Acute 
alcohol had no effects on sIPSC frequency. (D) Acute alcohol 
significantly decreased sIPSC amplitude. ..................................................................... 41 
Figure 2.5:  Acute bath-applied alcohol increased mini excitatory post 
synaptic currents (mEPSCs) in vPAG dopamine neurons.  (A) 
Representative mEPSC trace of baseline control. (B) Representative 
mEPSC trace after 10 minutes of alcohol wash-on. (C) Acute alcohol 
increased mEPSC frequency. (D) Acute alcohol had no effects on 
mEPSC amplitude. ....................................................................................................... 42 
 x 
Figure 2.6:  Acute bath-applied alcohol (50mM) increased firing rate of 
vPAG dopamine neurons in the cell-attached recording configuration.  
(A) Representative firing rate trace of baseline control. (B) 
Representative firing rate trace in the same neuron after 10 minutes of 
alcohol wash-on. (C) Alcohol increased firing rate in vPAG DA 
neurons.  (D) Alcohol had no significant effect on firing rate in the 
presence of NBQX (10µM). ......................................................................................... 43 
Figure 2.7:  Chronic intermittent alcohol vapor exposure did not affect 
inhibitory and excitatory synaptic properties.  (A) Representative 
mEPSC trace. (B) Representative mIPSC trace.  (C) Chronic 
intermittent alcohol had no effect on mini frequency. (D) Chronic 
intermittent alcohol had no effect on mini amplitude. (E) Chronic 
intermittent alcohol had no effect on mini excitatory/inhibitory 
transmission ratio. ........................................................................................................ 44 
Figure 3.1:  KOR-mediated signal transduction.  Receptor activation by a 
KOR-selective ligand can result in activation of several kinase 
cascades.  Arrows refer to activation steps, T line refer to blockers or 
inhibition of functions.  Abbreviations are as follows: α, G-protein 
alpha subunit; βγ, G-protein beta-gamma subunit; cAMP, cyclic 
adenosine monophosphate; ERK1/2, extra-cellular signal-regulated 
kinase; GRK3, G-protein coupled receptor kinase3; JNK, c-Jun N-
terminal Kinase; p38, p38 MAPK; p, phosphorylation;PI3K, 
phosphoinositol 3-kinase; PKCζ, protein kinase C zeta. ............................................... 63 
Figure 3.2:  KOR agonist, dynorphin A (300nM), decreases mIPSCs in 
vPAG DA neurons via KOR actions. (A) Representative mIPSC 
traces of baseline control (i) and after 10 minutes of 300nM 
dynorphin A wash-on (ii).  (B) Dynorphin A significantly decreased 
mIPSC frequency.  (C) Dynorphin A had no effect on mIPSC 
amplitude.  (D) Cumulative frequency of mIPSC was shifted towards 
longer interevent intervals by Dynorphin A.  (E) Cumulative 
probability of mIPSC amplitude was not affected by dynrophin 
A.  (F) Dynorphin A no longer decreased mIPSC frequency in the 
presence of nor-BNI (100nM).  (G) Dynorphin A had no effect on 
mIPSC amplitude in the presence of nor-BNI. (H) nor-BNI alone had 
no effect on mIPSC frequency.  (I) nor-BNI alone had no effect on 
mIPSC amplitude. ........................................................................................................ 64 
Figure 3.3:  The postsynaptic GPCR inhibitor, GDPβs (4mM), defused 
into the recorded vPAG DA neuron did not block dynorphin A from 
attenuating mIPSC, suggesting a presynaptic mechanism.  (A) 
Inhibition of postsynaptic GPCR did not block dynorphin A from 
attenuating mIPSC frequency.  (B) Dynorphin A had no effects on 
mIPSC amplitude in the presence of GDPβs. (C) GDPβs did not 
block dynorphin A’s ability to shift the mIPSC cumulative frequency 
 xi 
towards longer interevent intervals.  (D) Dynorphin A had no effect 
on mIPSC amplitude cumulative probability. ............................................................... 66 
Figure 3.4:  The ERK1/2 inhibitor SL327 (10 µM) and the p38 inhibitor 
SB203580 (20 µM) did not block dynorphin A from attenuating 
mIPSC.  (A) Dynorphin A significantly decreased mIPSC frequency 
in the presence of SL327.  (B) Dynorphin A had no effects on mIPSC 
amplitude in the presence of SL327.  (C) Dynorphin A significantly 
decreased mIPSC frequency in the presence of SB203580. (D) 
Dynorphin A significantly decreased mIPSC amplitude in the 
presence of SB203580. ................................................................................................ 67 
Figure 3.5:  KOR inhibition does not require calcium and potassium ion 
channels.  The GPCR βγ subunit inhibitor blocked dynorphin A from 
attenuating mIPSC.  (A) KOR/dynorphin A inhibition persisted even 
when all Ca
2+
 was removed by incubating slices in 0mM Ca
2+
/4mM 
Mg
2+
, 100µM EGTA with 50µM BAPTA-AM. (B) KOR/dynorphin 
A inhibition persisted even when all Ca
2+
 was removed  and K
+
 
channels are blocked with 4AP (100µM). (C) Gallein (100µM) 
prevented dynorphin A from inhibiting mIPSC frequency. mIPSC 
amplitude remained unaffected. ................................................................................... 68 
Figure 3.6:  The PI3 kinase inhibitor wortmannin (1µM) and the PKA 
inhibitor RP-camps (10µM) did not block dynorphin A from 
attenuating mIPSC.  (A) Dynorphin A significantly decreased mIPSC 
frequency but had no effect on amplitude in the presence of 
wortmannin.  (B) Dynorphin A decreased mIPSC frequency and had 
no effect on amplitude in the presence of RP-camps. ................................................... 69 
Figure 3.7: KOR presynaptically inhibit GABA release potentially via the 
disruption of functions in SNARE complex of the release machinery 
by the βγ subunit of the KOR GPCR. ........................................................................... 70 
Figure 4.1:  BNST receives dopamine projections from both the VTA and 
vPAG, while vPAG DA neurons co-expressing vGlut2 project to a 
sub-region of the dorsal BNST.  Injection of the retrograde tracer 
fluorogold (FG) into the BNST demonstrated that tyrosine 
hydroxylase (TH)-positive cells in the (A) VTA and (B) vPAG 
project to the BNST. Next, we stained for TH in a vGlut2-Ai3 
reporter mouse to illustrate that (C) dopamine neurons in the vPAG 
are also (D) vGlut2-positive.  (E) BNST images of vGlut2-Ai3 mice 
revealed that vGlut2-positive neurons terminals populated a sub-
region of the BNST that highly resembles the oval nucleus. ......................................... 90 
Figure 4.2: GABAergic and dopaminergic cell body distribution in the 
vPAG.  A GAD67-eGFP animal co-stained for TH demonstrated that 
dopaminergic neurons are located ventral and medial to the aqueduct, 
 xii 
and GABAergic neurons are situated laterally to the 
aqueduct.  Further, the GABAergic and dopaminergic neurons are 
distinct from one another and do not co-express. .......................................................... 91 
Figure 4.3:  Light-evoked action potential in the vPAG DA neurons.  A 
vGlut2-cre mouse was injected with a viral vector of double inverted 
channelrhodopsin(ChR2)-mcherry into the vPAG.  Transfected cell 
bodies in the vPAG that expressed mcherry were visualized and 
recorded from.  Blue light stimulation pulses varying in frequency 
were presented while the vPAG dopamine neurons fired in a time-
locked manner at corresponding frequencies of 1, 5, 10, 20, and 
40Hz. ........................................................................................................................... 93 
Figure 4.4:  Light-evoked glutamatergic current in the BNST neurons.  A 
vGlut2-cre mouse was injected with a viral vector of double inverted 
channelrhodopsin(ChR2)-mcherry into the vPAG.  Transfected 
vGlut2 terminals projected from the vPAG expressed mcherry and 
could be visualized in the BNST.  Neurons in proximity to clusters of 
mcherry-expressing terminals were recorded from.  Blue light 
stimulation pulses varying in frequency were presented while 
glutamatergic current were evoked in BNST neurons at 
corresponding frequencies of 1, 5, 10, 20, and 40Hz. ................................................... 95 
Figure 4.5:  Light-evoked GABAergic and glutamatergic currents in the 
BNST neurons. A TH-cre mouse was injected with a viral vector of 
double inverted channelrhodopsin(ChR2)-mcherry into the 
vPAG.  Transfected TH projections from the vPAG expressed 
mcherry and could be visualized in the BNST.  Neurons in proximity 
to clusters of mcherry-expressing terminals were recorded 
from.  Blue light stimulation pulses were presented and both (A) 
evoked-GABAergic and (B) evoked-glutamatergic currents were 
observed in BNST neurons. ......................................................................................... 96 
Figure 4.6:  Activation of vPAG TH-positive dopamine neurons produced 
a robust anti-nociceptive effect.  TH-cre and wild type animals were 
injected with viral vectors of double inverted Gq-coupled DREADD 
into the vPAG.  Upon activation of vPAG dopamine neurons via the 
injection of CNO prior to the Von Frey hyperalgesia test, TH-cre 
animals displayed a significant decrease in response to the 
hyperalgesia test than the wild type animals. ................................................................ 97 
Figure 4.7:  Activation of vPAG TH-positive dopamine neurons had no 
significant effects on open field assay.  Upon activation of vPAG 
dopamine neurons via the injection of CNO prior to the open test, 
there was no significant differences in A) total distance traveled, B) 
time spent in center, and C) entrance number to center between TH-
cre and wild type animals. ............................................................................................ 98 
 xiii 
Figure 4.8:  Activation of vPAG TH-positive dopamine neurons had no 
significant effects on elevated plus maze assay.  Upon activation of 
vPAG dopamine neurons via the injection of CNO prior to the open 
test, there was no significant differences in A) time spent in open 
arms, B) entry number to open arms, C) time spent in closed arms, 
and D) entry number to closed arms between TH-cre and wild type 
animals. ....................................................................................................................... 99 
Figure 4.9:  Activation of vPAG TH-positive dopamine neurons had no 
significant effects on light/dark box assay.  Upon activation of vPAG 
dopamine neurons via the injection of CNO prior to the open test, 
there was no significant differences in A) time spent in light 
compartment, B) entry number to light compartment, C) time spent in 
dark compartment, and D) entry number to dark compartment 
between TH-cre and wild type animals. ..................................................................... 100 
 xiv 
LIST OF ABBREVIATIONS 
BNST   bed nucleus of the stria terminalis 
cAMP   cyclic adenosine monophosphate 
DA   dopamine 
ERK   extracellular signal-regulated kinase 
GABA   gamma-aminobutyric acid 
GRK3   G-protein coupled receptor kinase3 
JNK    c-Jun N-terminal Kinase 
mEPSC  mini excitatory post-synaptic current 
mIPSC   mini inhibitory post-synaptic current 
PI3K   phosphoinositide 3-kinase 
PKA   protein kinase A 
PKCζ    protein kinase C zeta 
SEM   standard error of the mean 
sIPSC   spontaneous inhibitory post-synaptic current 
TH   tyrosine hydroxylase 
vPAG   ventral portion of the periaqueductal gray 
VTA   ventral tegmental area 
 CHAPTER 1. GENERAL INTRODUCTION 
DOPAMINE SIGNALING 
For well over three decades, dopamine (DA) signaling has been known to play a 
critical role in reward and motivation, as well as the establishment of stimulus-reward 
association (1-3).  Dopamine release in the striatal structures can be increased by reward, 
such as food, drug intake and sexual behavior, while dopamine antagonists can prevent 
these behaviors (4-7).  Reward association, such as the ability to be trained to lever-press 
for naturally rewarding things as food, water or sexual contact, requires dopamine 
signaling, as reward association cannot be learned when dopamine function is impaired 
(8).  Additionally, previously acquired stimulus-reward associative learning cannot be 
continued or maintained when dopamine systems are blocked (2, 9, 10).  The DA 
pathways that modulate behavioral responses to environmental stimuli are central to the 
signaling of reward.   
These pathways include dopamine neurons in midbrain nuclei such as the ventral 
tegmental area (VTA) and the substantia nigra pars compacta (SN) that project to striatal 
structures, (nucleus accumbens, NAc, and the dorsal striatum), limbic structures 
(amygdala and hippocampus), and cortical regions.   Drug and food reward have been 
shown to lead to an increase in dopamine levels in the nucleus accumbens (11-13), 
suggesting that dopamine signaling to this nucleus from the VTA plays an important role 
 2 
in the rewarding properties of these stimuli.  Further, selective chemical lesions of NAc-
projecting dopamine neurons lead to the attenuation of the rewarding effects of cocaine 
and amphetamine (14), while this effect was not found in animals with ablation of 
norepinephrine-expressing neurons.  Dopamine pathways regulate motivational behaviors, 
demonstrated by motivational deficits in feeding and water drinking caused by dopamine 
lesions in the lateral hypothalamus (15).  Striatal pathways regulate movement and 
reward: the dopamine D1-mediated direct pathway promotes movement and reward while 
the dopamine D2-mediated indirect pathway activation increases immobility and appears 
to serve as punishment (16, 17).   
Dopamine is generally thought to play a critical role in the formation and 
maintenance of addictive behaviors in drug use (18-21), but despite the large body of 
evidence supporting this notion, the necessity of dopamine signaling in all drug reward 
remains controversial.  Several drugs of abuse such as phencyclidine (22), morphine (23), 
and nicotine (24) have demonstrated both dopamine-dependent and dopamine-
independent rewarding effects.  Taken together, the importance of dopamine in reward-
related behavior is undeniable; however, dopamine might not be required or limited to 
reward behaviors as studies find dopamine involvement in other complex emotional 
behaviors and conditions. 
Many psychiatric and neurological disorders have been associated with a severe 
dysregulation of the brain reward system.  There are strong correlations between 
movement, reinforcement, and reward in many neurological and psychiatric diseases, 
such as Parkinson’s disease and Schizophrenia.  Depression is a common symptom of 
Parkinson’s disease (25) and is described in the Diagnostic and Statistical Manual of 
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Mental Disorders (DSM-IV-TR2000) by deficits in reward function, coupled with 
heightened punishment from negative consequences.  Depressive individuals often 
display psychomotor retardation, consisting of slowing of speech, eye and body 
movement, as well as abnormal body posture and facial expressions (26, 27), overlapping 
with the symptoms of Parkinson’s disease caused by dopamine deficiencies.  
Interestingly, these motor abnormalities caused by dopamine deficiencies in Parkinson’s 
disease can be alleviated by dopamine agonists (28).  In addition, medications for 
Parkinson’s disease that improve motor deficits, such as dopamine agonists and 
monoamine oxide inhibitors, have also been found to relieve Parkinson-associated 
depression (29-31).   
Depression is one of many negative emotional disorders modulated by dopamine; 
studies have shown that dopamine neurons can also modulate negative affective states 
such as anxiety.  In these studies, select inhibition of VTA dopamine neurons induced 
depressive-like phenotype (32), and the ablation of kappa opioid receptors in dopamine 
neurons decreased anxiety-like effects in the open field and light/dark box behavioral 
assays (33).  Additionally, dopamine D3 knockout animals display a decrease in 
depression-like behavior after immobilization stress (34).  This evidence demonstrates 
the involvement of dopamine signaling in negative affective disorders, suggesting a 
regulatory role of dopamine signaling in not only reward, but also the development and 
maintenance of negative emotions.  
The majority of dopamine research leans heavily on the mesolimbic and striatal 
pathways mentioned earlier.  However, recent studies suggested that other populations of 
dopamine neurons in the midbrain are positioned to regulate both addiction and negative 
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affective disorders.  The following section discusses the periaqueductal gray and its role 
in dopamine signaling. 
PERIAQUEDUCTAL GRAY 
The periaqueductal gray is a highly heterogeneous brain region; in addition to the 
dopamine neurons, there are large populations of GABAergic and glutamatergic neurons 
(35).  Due to the diversity of its cell types, the PAG also has a variety of functional 
outputs that modulate a wide array of behaviors, including reward and autonomic 
functions, as well as negative affective behaviors such as panic and aggression.  The 
PAG’s complex composition presents difficulties when trying to isolate neural networks 
and examine the functions of specific cell types.  With the advent of transgenic animal 
models, as well as viral tools, the roles of periaqueductal gray neurons are slowly being 
unraveled.   
The involvement of the PAG in both reward and negative affect position this 
structure in a critical role of modulating drug-seeking behaviors and the associated 
negative emotional behaviors that often accompany withdrawal.  In support of this 
possibility, recent studies have revealed projections from the PAG to regions involved in 
reward circuits, including the VTA, and the SN (36). Such studies have also illustrated 
synaptic connections onto specific populations of VTA neurons, including dopaminergic 
neurons (37), further demonstrating a role of this projection in the rewarding effects of 
drugs.  In addition to reward-related behaviors, recent studies suggest the existence of a 
PAG dopaminergic projection to brain structures known to regulate negative emotions.  
An example of such a structure is the bed nucleus of the stria terminalis (BNST), where 
dopamine and corticotropin-releasing factor (CRF) interact to regulate fear and anxiety 
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(38).  Other studies have shown that modulation in the PAG can influence emotional 
behavior: antagonism of the GABA receptors in the PAG increases anxiety-like behavior 
(39).  Further, the sensitization of the PAG has been shown to suppress positive affect in 
rats (40), suggesting that increased activity in the PAG is heavily engaged during 
production of negative emotional behaviors and the maintenance of negative affective 
states.  The PAG is also an important site in the ascending nociceptive control (ANC) 
pathway projecting to the rostral ventral medulla and there by regulates pain-related 
behaviors (41).  There is evidence that dopamine neurons in the PAG may potentially 
play a role in the ANC as opiate anti-nociception is attenuated upon chemical lesion of 
PAG dopamine neurons (42).  The PAG DA-mediated negative emotional behaviors 
mentioned above often display high comorbidity with one another, as stress (43), anxiety 
(44), and depression (45), have all been shown to exacerbate pain perception, and vice 
versa, suggesting that the regulation of these negative affects and their projections could 
be modulated in a similar fashion by certain groups of PAG DA neurons. 
Another PAG dopamine-mediated behavior heavily linked to a negative 
emotional state is sleep.  Selective chemical lesioning of dopamine neurons in the PAG 
leads to an increase in sleep time (46), illustrating the critical role of PAG dopamine 
projections to the prefrontal cortex in sleeping behavior.  At the same time, deprivation of 
sleep is tightly associated with emotions such as stress (47), anxiety (48), depression (49), 
as well as pain (50), negative affective states already known to be influenced by PAG 
dopamine neurons.  Given the knowledge of the cell-type diversity in PAG and its 
projections to a variety of brain regions linked to negative affects that are closely 
associated with one another, the PAG has become a region of interest for the treatment of 
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affective disorders.  Other behaviors mediated by PAG includes defensive behaviors (51), 
cardiovascular functions via its projections to the hypothalamus (52, 53), and lordosis 
behavior in sexual courtship (54).   
As mentioned earlier, dopamine signaling mediates the rewarding properties of 
drugs of abuse, including alcohol.  An abundance of evidence highlight the importance of 
the role the PAG plays in the negative affect specifically associated with alcohol abuse.  
Withdrawal following chronic ethanol exposure can induce hyperalgesia (55), suggesting 
a link between the PAG ascending nociceptive pathway and alcohol abuse.  Further, 
dorsal PAG stimulation-induced freezing and escape was sensitized during ethanol 
withdrawal (56), and neurons in the PAG are critically involved in the neural circuitry for 
audiogenic ethanol withdrawal seizures (57).  Taken together, this evidence illustrates 
that PAG-mediated behaviors can be altered by prolonged alcohol exposure.  
Additionally, alcohol can affect neural activity in the PAG, causing increased action 
potential frequency and hyper-excitability in PAG neurons during ethanol withdrawal 
(58).  These studies provide essential information that links PAG function to alcohol 
abuse and related negative affects.  It is important to note that the PAG has also been 
implicated in the withdrawal from diazepam (59) and opiates (60), both of which are 
popular substances of abuse.  Given the recent findings that dopamine neurons in the 
PAG project to areas sensitive to drugs of abuse, it is compelling to investigate the 
modulation and functions of these A10dc dopamine neurons.   
Several inputs of the PAG have been identified to play important roles in 
modulating PAG neural activity.  Consistent with the knowledge that the PAG mediates 
negative emotional behaviors through projections to the extended amygdala (the BNST 
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and central amygdala), a number of studies have demonstrated projections from the 
extended amygdala onto the PAG in regulating negative emotional behaviors as well (61-
63).  These extended amygdala projections to the PAG have been demonstrated to be 
GABA-mediated inhibitory inputs and modulate anxiety-like behaviors (38, 64, 65).  In 
addition, studies have demonstrated a population of tonically active GABAergic neurons 
in the lateral portion of the PAG (66).  Although local GABAergic interneurons have 
been shown to inhibit dopamine projection neurons in other dopamine-rich brain regions 
such as the VTA (67), the role of this local population of GABAergic neurons on vPAG 
dopamine neurons is unclear.  The PAG also receives glutamatergic inputs from the 
lateral habenula (68, 69) that are associated with pain (70, 71), defensive behaviors (72), 
and sleep (73), and other projections to the PAG have also been found from the prefrontal 
cortex (74) and the brain stem (75, 76).  These studies identified some projections that 
could contribute to the modulation of PAG-mediated behaviors; however, despite all the 
anatomical and synaptic studies conducted in the PAG, specific dopamine neuron-
modulation has yet to be investigated due to the heterogeneity of the PAG.  The 
investigation of how drugs of abuse modulate the PAG requires a thorough understanding 
of the actions of drugs, as well as their effects on neural networks and substrate alteration.  
The following section focuses on the effects of acute and chronic alcohol. 
ALCOHOL 
 Alcohol addiction 
Addiction is defined by the continuous use of a substance despite its negative 
consequences.  Alcohol dependence is diagnosed based on three or more of the following 
criteria outlined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, 
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1994): tolerance, withdrawal, drinking a larger amount or longer period than intended, 
inability to control use, a large amount of time spent in alcohol-seeking and related 
activities, missing important social/occupational/recreational activities due to alcohol use, 
as well as the continuation of use despite knowledge of having persistent physical or 
psychological problems caused by alcohol.  Initially, alcohol consumption seems to be 
driven largely by its positive reinforcing effects (i.e. the euphoric effects of ethanol) (77).  
Over prolonged exposure, there is a proposed shift to a negative reinforcement, as 
negative affect is increased due to withdrawal.  It is believed that the negative affective 
state drives an individual’s consumption of ethanol to alleviate the symptoms (78), 
creating a vicious cycle strengthened by repeated exposure.  The negative affective 
disorders induced by ethanol exposure include depression (79, 80), anxiety (81), panic 
disorder (82), stress (83-85), and pain (86).  The manifestation of these psychiatric 
disorders has been shown to render an individual more prone to relapse, and could cause 
relapse even long after the withdrawal period (87, 88).  Additionally, repeated ethanol 
withdrawal episodes enhance negative affective symptoms (89).  Due to the causative 
relationship between negative mood states and ethanol use, individuals easily fall into a 
cyclic addictive behavior pattern.  The high comorbidity of alcohol addiction and 
negative mood disorders often presents difficulties in the treatment of alcohol abuse; 
therefore, understanding the mechanisms underlying the formation of these negative 
affective symptoms and their modulation is critical for the treatment of alcoholism. 
 Acute Alcohol 
Acute alcohol interacts with a variety of presynaptic and postsynaptic proteins to 
modulate synaptic activity, often altering the balance between inhibitory and excitatory 
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transmission.  A large body of evidence shows that acute alcohol enhances the function 
of Cys-loop ligand-gated ion channels (LGIC) (90, 91).  Among the various types of 
LGIC are the inhibitory glycine receptors and GABAA receptors.  While the majority of 
studies show alcohol-induced enhancement of LGIC functions, a few of exceptions show 
an inhibition of GABAARs (92, 93) and other LGICs (94, 95) upon acute application of 
alcohol.  Putatively, alcohol enhances ion channels by either increasing agonist affinity 
(96) or encouraging the state of open channels (97).  It has been shown that alcohol 
increases GABA-mediated inhibitory current amplitude and duration in the brain stem 
(98, 99), the basolateral amygdala (100, 101), the central amygdala (102), the 
hippocampus (103), and the cerebellum (104).  Both glycine and GABAA receptors 
mediate inhibitory chloride currents, and both receptors are pentameric receptors that can 
be composed of a wide range of subunits and subunit compositions.  Each subunit type 
can further be differentiated into numeric-variations, which can alter the pharmacological 
and electrophysiological properties of receptors.  Acute alcohol can modulate channels 
both synaptically (98, 105, 106) and extra-synaptically (107-109);  synaptic GABAA 
receptors are composed of two α, two β, and one γ subunits, while extra-synaptic GABAA 
receptors are high affinity receptors (110) and contain a δ subunit instead of γ.  Alcohol 
has been reported to modulate GABA receptors containing specific subunit compositions, 
such as α/β/γ-subunit-containing receptors, as well as those containing α4 or α6 along 
with β and δ subunits (111-113).  Potentiation of glycine-mediated tonic current by 
alcohol has been observed in the cerebellum (110), the hippocampus (114, 115), and the 
thalamus (116) in a subunit composition-dependent manner (117, 118).     
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Opposite from the impact on inhibitory transmission, acute alcohol has 
consistently been shown to exert inhibitory actions on excitatory cation-permeable 
ionotropic glutamate receptors: the AMPA receptors, the NMDA receptors, and the 
kainite receptors (119).  Alcohol-inhibition on NMDARs has been observed in many 
brain regions, from the hippocampus to the amygdala, as well as the cerebellum (120-
123).  Much like the inhibitory receptors, alcohol also affects NMDA receptors 
differentially in a subunit-dependent manner.  NMDA receptors are tetrameric and are 
composed of an obligatory NR1 subunit, in combination with at least one NR2 or NR3 
subunit.  The combination of different splice variations of the NR1 and accompanying 
NR2 can account for alcohol sensitivity (124), and although receptors containing NR3 
subunit are relatively insensitive, the combination with NR2B could overcome the 
presence of NR3-insensitivity and enhance alcohol-induced inhibition (124).  
Glutamatergic AMPA receptors are inhibited by alcohol as well; however the impact of 
inhibition of AMPA receptors is not as robust as NMDA receptors (125-127).  In addition, 
subunit composition of AMPA receptors has minimal influences on alcohol sensitivity 
(128), which could be due to alcohol-induced receptor desensitization (129).  The above 
evidence suggests that acute alcohol has a consistent effect on ionotropic glutamatergic 
receptors and decreases glutamatergic currents. 
Long-lasting changes in synaptic transmission could contribute to the formation 
of addiction (130), and are usually produced by repeated activation of specific pathways.  
The ability of acute alcohol to augment inhibitory tone to attenuate excitatory 
transmission explains the observation that long-term potentiation (LTP) in transmission is 
suppressed by alcohol in the hippocampus (131) and the amygdala (132). These data raise 
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the potential of acute alcohol to induce synaptic plasticity in areas known to regulate 
learning and memory, as well as negative emotional behaviors, all of which are highly 
correlated with alcohol addiction (133). 
Chronic Alcohol 
Prolonged alcohol exposure often results in two behavioral alterations: tolerance 
and dependence.  These changes make the treatment of alcoholism more difficult, as 
tolerance encourages overuse due to the physiological habituation to lower doses, and 
dependence is diagnosed during withdrawal when individuals experience negative affect 
such as pain, anxiety, sleep loss, and seizure in the absence of alcohol.  Both of these 
behavioral modifications encourage continuing alcohol usage to achieve the desired 
intoxication level, as well as to avoid the negative affect of withdrawal.  Changes in 
behavior arise due to shifts in synaptic transmission in neural pathways in a variety of 
brain regions.  In this section, the effects of chronic alcohol are addressed in the context 
of the balance between inhibitory and excitatory transmission.  It is important to note 
however, that there are many different chronic alcohol exposure and withdrawal 
paradigms.  Depending on the brain region, experimental design, length of exposure, 
number of repeated withdrawals, as well as the time point during withdrawal, a large 
discrepancy can be observed in the results. 
There has been some evidence that chronic alcohol can modulate presynaptic 
GABA release.  Some evidences show that chronic alcohol can modulate presynaptic 
GABA release in brain regions such as the hippocampus where a reduction in long-term 
potentiation was observed via an increase in the evoked release of tritiated GABA 
without affecting uptake (134).  Studies in the central amygdala (CeA) suggest that there 
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is an increase in evoked GABA release, as well as an enhancement of mIPSC in CeA 
neurons after chronic alcohol.  Further, dependent animals show dramatically increased 
GABA release in the CeA upon in vivo microinjection of alcohol directly into the CeA 
relative to naïve animals, suggesting an increase GABAergic tone after chronic alcohol 
exposure (135, 136).  In contrast, some studies show that voluntary drinking is associated 
with a significant increase in paired-pulse ratio, suggesting a decrease in GABA release 
probability in the dentate gyrus neurons of monkeys (137).  Together, these studies 
demonstrate that chronic alcohol can alter presynaptic GABA release.   
In contrast, a large body of studies has found a significant impact of chronic 
alcohol on postsynaptic GABAergic transmission.  GABA receptor subunit expression 
has been found to change after chronic alcohol exposure and affect receptor composition, 
functions, and binding.  For instance, in the cerebral cortex, chronic alcohol has been 
shown to differentially alter mRNA and protein expression.  Specifically, levels of α1, α2, 
and α3 were decreased after chronic alcohol exposure, while α4, β1, β2, β3, γ1 and γ2 
subunit levels were increased (138, 139).  Results in the cerebellum mRNA expression 
are consistent with decreases in the α1 subunit and increases in the α6 following chronic 
ethanol exposure (139, 140).  Chronic ethanol administration also decreased polypeptide 
levels of the δ subunit in the rat cerebellum and hippocampus, but not in the cerebral 
cortex (141).  Notably, the majority of results from hippocampus and cerebral cortex 
studies are exposure- and time point-dependent (139, 142).  Likewise, in the VTA, α1 
subunit immunoreactivity was decreased in a 12-week exposure paradigm, but not a 1-4 
week paradigm (143, 144).  Both α1 and α4 immunoreactivity decreased in the amygdala 
after two weeks of alcohol exposure, while in the nucleus accumbens, α4 decreased and 
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α1 levels remained unchanged (144).  In addition to the alteration in receptor subunit 
expression, other proteins could play important modulatory roles in receptor initiation 
and trafficking, altering receptor functions after chronic alcohol.  These modulatory 
proteins include clathrin and adaptor complex, which are crucial for GABAA receptor 
internalization (145-147).  Protein kinases such as PKA, PKC, and fyn could regulate 
GABAA receptor trafficking, and chronic alcohol has been shown to decrease associate of 
PKCγ with the α1 GABAA subunit, and increase associate with α4 in the cerebral cortex 
(148).  This, however, was not observed in the hippocampus (145).  The association 
between PKCγ and the α4 subunit could lead to GABAA receptor phosphorylation and 
disrupt recognition by the adaptor complex, thus preventing its internalization (147).   
It is clear that receptor composition and expression can be altered by chronic 
alcohol exposure.  However, it does so in a relatively region-specific manner, and is 
sensitive to the duration of ethanol exposure and time point during withdrawal.  As 
GABA receptor properties is highly correlated with receptor functions, studies in the 
monkey hippocampus demonstrated a significant increase in paired-pulse facilitation of 
GABA-mediated IPSC following 18 months of daily alcohol intake (149).  This finding is 
consistent with a decrease in release probability mentioned earlier, as well as the decrease 
in mIPSC frequency found in rats after chronic intermittent alcohol exposure (150).  In 
the central amygdala, after 2-3 weeks of chronic alcohol vapor treatments, it was shown 
that evoked IPSCS in alcohol-dependent rats were significantly larger than those in naïve 
rats, suggesting a postsynaptic-mediated mechanism (135).  As mentioned earlier, this 
research group also found a higher mIPSC frequency in alcohol-dependent animals, 
suggesting an increase in GABA release in the rat amygdala.  Together, these data 
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suggest that both pre- and post-synaptic GABA transmission can be altered by chronic 
alcohol exposure.   
In contrast to acute alcohol’s effects on excitatory inputs, chronic alcohol 
exposure leads to a general increase in glutamatergic transmission (151, 152).  However, 
similar to the acute effects of alcohol, NMDA receptors are modulated by chronic alcohol 
in a more robust fashion than other types of glutamatergic receptors (153, 154).  Both in 
vivo and ex vivo chronic alcohol exposures induce increases in NMDAR functions, and 
subsequent increases in neuronal calcium (155) and nitric oxide (153) signals.  The 
NMDAR subunit NR2B has been identified as important in the chronic alcohol-induced 
enhancement of NMDAR-mediated current (156-158).  While chronic alcohol augments 
excitatory transmission, acute alcohol still produces glutamatergic-inhibition after 
chronic exposure, but to a smaller extent (159, 160). Some studies have shown increases 
of specific NMDA subunits after chronic alcohol exposure using immunohistochemistry, 
particularly the alcohol-sensitive NR2B, and different splice variation of the NR2A (161, 
162).  Others have shown increases in mRNA expression levels of different splice 
variants of the NR1 subunit (156, 163, 164).  However, other studies do not report these 
NMDA receptor changes after chronic alcohol exposure.  In addition to NMDA receptors, 
AMPA receptors have also been reported to increase, as evidenced by increases in 
mRNA (165) and protein expression (166), as well as increase in binding (167) following 
chronic alcohol exposure. Further, an enhancement of AMPAR functions has also been 
reported in the cerebellum (168) and the amygdala (152).  Chronic alcohol-induced 
enhancement of kainate receptor function was found in the hippocampus (169) and the 
amygdala (170), but not in primary cortical neurons (166).  Lastly, chronic alcohol has 
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been shown to increase mGluR-mediated signaling, as well as protein expression, 
particularly mGluR1 and mGluR5 (162, 171, 172).  
The above section detailed chronic alcohol exposure’s ability to modulate both 
inhibitory and excitatory transmission, as well as illustrated how the balance between 
inhibitory and excitatory inputs could be altered by chronic alcohol in brain region- and 
duration- dependent manners.  It is clear that more studies are needed to further isolate 
the regulation of specific pathways and projections in order to better link them to the 
behavioral changes accompanied by chronic alcohol use in humans.  The following 
section discusses the kappa opioid receptor and how it can modulate drinking behaviors. 
KAPPA OPIOID RECEPTORS 
As a member of the opioid receptor family, kappa opioid receptor (KOR) actions 
have been shown to play important roles in analgesia, mood modulation, and addiction.  
The KORs are widely spread throughout the brain, spinal cord, and peripheral systems, 
and are activated via opioid peptides derived from prodynorphin, such as dynorphin A (1-
17) and dynorphin B (1-13) (173, 174).  KOR activation involves coupling to the 
inhibitory G-protein Gi/o to inhibit adenylyl cyclase through the dissociation of the α 
subunit.  The βγ subunits modulate ion channels to increase potassium conductance and 
decrease calcium conductance (175).  The kappa opioid receptors can also be 
phosphorylated and activate downstream signaling cascade (See Chapter IV for signaling 
cascade).  Kappa opioid receptor ligands are inhibitory neuropeptides that hyperpolarize 
neurons (176, 177), as are other members of the opioid family.  It has been shown that 
kappa opioid receptors can presynaptically inhibit both GABAergic inputs (178, 179), 
and glutamatergic inputs (180, 181), as well as the signaling of dopamine, norepinephrine, 
 16 
and serotonin (182-185).  KORs have been shown to locate presynaptically on 
dopaminergic input to the amygdala, NAc, and PFC (186-188); on GABAergic inputs to 
the NAc and the extended amygdala (central nucleus of the amygdala and BNST) (189); 
on glutamatergic inputs to the VTA and NAc (189) and on serotonergic inputs to the NAc 
(182), as well as on noadrenergic inputs to the PFC (190).  The KORs have also been 
found on the cell bodies of dorsal raphe serotonin (5-HT) neurons (182), locus coeruleus 
norepinephrine neurons (191), as well as VTA mesocortical dopamine neurons (192).  
Mechanistically, it has been shown that kappa opioid receptor activation has the ability to 
modulate dopaminergic neurons in the VTA.  More specifically, a KOR agonist can 
inhibit the VTA DA neurons projecting to the prefrontal cortex, but not projections to the 
amygdala (192).  Interestingly, while isolating GABA-mediated inhibitory post-synaptic 
currents (IPSCs) in the VTA dopamine neurons, the same research group found that 
opioid agonists also inhibited GABAergic transmission.   The KOR system is widely 
distributed in the central nervous system and has been implicated in numerous 
pathophysiological disorders associated with mood and motivation (193-196), pointing to 
its potential as a putative therapeutic target for neuropsychiatric disorders. 
Behavioral phenotypes of KOR activation are of particular interest due to its 
potential for serving as a target in the treatment of addiction and affective disorders.  
Effects of KOR activation include drug-seeking behavior (182) and analgesia (197), as 
well as dysphoric affect such as depression (198), stress and anxiety-like behaviors (199, 
200), and most importantly, dependence-induced depressive-like behaviors (201).  Many 
of the KOR-relevant emotional behaviors are modulated in the mid brain region, namely 
in the VTA, vPAG, and dorsal raphe.  In particular, dopaminergic neurons and their 
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regulation seem to play a critical role in these negative affective disorders.  Studies have 
shown that KOR activation in the dorsal raphe, which also contains A10dc dopamine 
neurons and is just ventral of the vPAG, produces conditioned place aversion (202), and 
mediates the aversive effects of stress, and reinstates drug-seeking (182).  In addition, 
KOR knockouts and conditional knockouts in dopamine-containing neurons produced 
anxiolytic-like effects and enhanced cocaine-induced plasticity (33).  Depressive-like 
effects of the KOR agonist salvinorin A have also been shown associated with decreased 
phasic dopamine release in the NAc (203).  Further, anti-nociception induced by oxytocin 
can be blocked by KOR antagonism in the PAG (204).  The above evidence suggests that 
KOR actions can modulate negative emotions and drug-seeking behaviors, some of 
which are mediated via dopamine signaling. As mentioned earlier, dopamine signaling 
plays a critical role in reward and some negative emotional behaviors.  In addition, the 
PAG is a brain region highly implicated in both drug addiction and negative affect.  
Given the evidence that kappa opioid receptors are distributed widely in the PAG (205), 
and that KOR actions can modulate dopamine signaling, the PAG becomes a critical 
brain region to study to better understand the mechanisms underlying drug addiction-
associated mood disorders.  More research on KOR modulation of neural activity in the 
PAG will allow us to better adapt strategies to develop treatment for negative mood 
disorders and alcoholism. 
KAPPA OPIOID RECEPTORS AND ALCOHOLISM 
Kappa opioid receptor activation not only produces negative affect similar to 
ethanol withdrawal, numerous studies provide direct links between KOR actions and 
ethanol intake.  Interestingly, alcohol exposure can lead to an up-regulation in KOR 
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signaling at the receptor level, as well as the ligand level (206).  Microdialysis studies 
show that acute alcohol can stimulate the release of opiates, including dynorphin, in 
regions implicated in reward and affective disorders such as the VTA, the amygdala, and 
the nucleus accumbens (207-211).  In addition, radioimmunoassay studies demonstrated 
that a 6-week chronic alcohol exposure significantly increased dynorphin B levels in the 
hypothalamus and substantia nigra, while it was decreased in the prefrontal cortex (212).  
Vice versa, KOR functions have also been shown to modulate alcohol-related behaviors.  
KOR activation mediates aversive effects produced by alcohol challenge (213), and 
systemic antagonism of KOR also attenuates dependence-induced excessive ethanol self-
administration in rats (214).  It also seems that KOR systems can modulate dopamine 
mediated reward-seeking behavior, as acute KOR activation decreases the rewarding 
properties of alcohol (215) while decreasing operant responding to ethanol (215).  
Interestingly, one study using a dopamine neuron-specific prodynorphin knockout mouse 
found an increase in voluntary ethanol intake, higher blood ethanol levels, and higher 
ethanol-conditioned place preference (216).  This result seems to oppose other studies 
mentioned earlier where KOR antagonism decreased dependence-induced drinking, 
however, this research group identified some critical receptor- and cellular modulation 
due to the genetic knockout.  Specifically, they found that dopamine tyrosine hydroxylase 
expression was decreased and dopamine transporter levels were increased.  In addition, 
proenkephalin (the endogenous precursor of the mu opioid ligand) expression decreased.  
This study showed the importance of dynorphin signaling in the maintenance of alcohol 
intake, as well as dopamine signaling.  Further, other studies have shown that dynorphin 
plays a critical role in the modulation of the brain stress-response system after chronic 
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alcohol exposure.  Long-term alcohol exposure elevated foot-shock-induced c-Fos 
expression in the basolateral amygdala in wild type mice, but had the opposite effect in 
dynorphin-knockout mice (217).  Just as opioid-inhibition of presynaptic GABAergic 
inputs onto VTA dopamine neurons can lead to the activation of dopamine neurons (67, 
176), similar effects have been demonstrated by acute ethanol.  In both the VTA (218) 
and the substantia nigra (SN) (219), it has been shown that acute ethanol stimulates the 
firing rate of dopamine neurons and inhibits GABAergic inhibitory currents.  Recent data 
has suggested that ethanol differentially impacts populations of dopamine neurons by 
brain region.  In a chronic vapor ethanol exposure paradigm, studies have shown that 
chronic alcohol exposure alters dopamine transporter (DAT) expression in the NAc, but 
not the striatum or the BNST (220), suggesting differential modulatory systems for 
dopamine neurons of different projections.  Given the important role that KOR signaling 
plays in the development and maintenance of alcoholism, understanding the mechanisms 
underlying KOR modulation of dopamine signaling could shed some light onto the 
development of treatments for alcohol abuse, as well as battle against the vicious cycle 
encouraged by withdrawal-induced negative affects. 
DISSERTATION 
The focus of this dissertation will be to characterize the properties and functions 
of vPAG DA neurons and to evaluate alcohol and kappa opioid modulation of dopamine 
signaling, as well as the underlying mechanisms thereof.  Clinically, related work has 
established the importance of understanding the negative affect produced from drug 
withdrawal, as they often lead to relapse, rendering treatment for addiction inefficient and 
the results short-lasting.  Understanding how substances of abuse modulate emotional 
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behavior circuits could shed light onto the development of more effective 
treatments.  The dopamine signaling system mediates the rewarding properties of drugs 
of abuse.  Evidence shows that alcohol exposure induces alterations in the signaling of 
dopamine-rich brain regions, such as the VTA.  While the kappa opioid system is known 
to mediate negative affect, a rather novel population of dopamine neurons in the vPAG 
has been shown to project to regions regulating negative emotions such as stress, anxiety, 
and depression.  Thus, it is likely that prolonged exposure to alcohol could increase 
vPAG dopamine signaling, consequently exciting stress and anxiety nuclei, and inducing 
stress- and anxiety-like behaviors.   
The following work will investigate the impact of both acute and chronic 
intermittent alcohol on vPAG dopamine synaptic transmissions.  Once the link between 
alcohol exposure and neural alteration is established, this study will investigate the 
modulation of vPAG dopamine neurons by KOR, putatively known to induce negative 
emotional behaviors when activated.  Based on previous studies of opioid modulations, it 
is likely that KOR activation will inhibit GABAergic inputs presynaptic to vPAG 
dopamine neurons, hypothetically increasing their activity, as well as increasing 
dopamine release in their projection areas (i.e. anxiety and stress centers), thereby 
promoting negative affects.  Following neural modulation, signaling mechanisms through 
which KOR activation alter neural transmission will be examined.  KOR activation 
triggers an array of signaling cascades mediated through the Gi/o-protein coupled 
receptors; this work will discern the loci of mechanism by inhibition of individual 
signaling pathways.  It was hypothesized that the MAP kinase ERK1/2 mediates the KOR 
activation-induced attenuation of inhibitory transmission, based on previous studies in the 
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BNST.  In addition, this work aims to examine the ability of vPAG DA neurons to 
modulate its projection area- the BNST.  It has been shown in the VTA that inhibition of 
presynaptic GABA inputs on to dopamine neurons increases dopamine release in 
projection area such as the NAc.  Thus, transmission in the BNST will be examined while 
stimulating vPAG DA inputs.  The overall hypothesis of this dissertation is that both 
alcohol and KOR-activation modulate vPAG dopamine synaptic transmission and neural 
activity, inducing alterations in regulation of its projection area – the stress center BNST. 
 CHAPTER 2. EFFECTS OF ALCOHOL ON VPAG DOPAMINE NEURON 
INTRODUCTION 
Alcohol use disorders are an enormous public health problem, and understanding 
the neurochemical systems involved in regulating the actions of alcohol can provide 
insight for the development of more effective treatments.  Numerous reports have 
suggested that the subjective response to acute alcohol is related to the risk of 
development of alcohol use disorders (221).  As such, understanding the actions of acute 
alcohol is an important area of investigation.  Animal studies have shown that acute 
alcohol can induce locomotor stimulation (222-224) and is also anxiolytic (225, 226).  
Alcohol also modulates pain perception and the anti-nociceptive effects of opiates (227).  
Chronic alcohol exposure produces much different behavioral effects during withdrawal.  
Locomotor activity has been reported to decrease (228), and anxiety-like behaviors are 
observed (229) during withdrawal period.  Other withdrawal-induced behaviors include 
aggression (230, 231), anhedonia (232), insomnia (233), and increased sensitivity to pain 
(55, 234). Given the diversity of these behavioral outcomes, there are likely multiple 
brain regions and their projection regions that are modulated by alcohol exposure.   
A large body of evidence suggests that dopamine (DA) signaling plays a critical 
role in mediating the rewarding aspects of acute alcohol. Much of this research has 
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focused on the mesolimbic DA system, which is composed of DA neurons in the ventral 
tegmental area (VTA)  that project to the nucleus accumbens (235, 236). However, recent 
studies have shown that dopamine signaling in other brain regions critical to alcohol 
abuse, such as the extended amygdala (237), can play an important role in alcohol reward.  
Interestingly, the extended amygdala receives a strong dopaminergic projection from the 
A10dc DA neurons, located in the ventral periaqueductal gray (vPAG), and dorsal raphe 
nucleus (DRN) (38, 238). The vPAG is particularly relevant as a target for the acute 
actions of alcohol as it has been implicated in the regulation of arousal (231, 239), 
anxiety (240-242), sleep (46), pain (42, 243-245), and opiate reward (246). Despite the 
potential behavioral relevance of vPAG DA neurons to the actions of alcohol, there have 
been no studies examining either the properties of these neurons, or the ability of alcohol 
to modulate their function.  In this study, we utilized a TH-eGFP transgenic mouse to 
selectively record from DA neurons in the vPAG and VTA for cell property comparison, 
as well as evaluating the impact of both acute and chronic alcohol on vPAG DA synaptic 
transmission. 
With the knowledge that vPAG DA neurons project to the extended amygdala and 
pharmacological blockade of dopamine receptors in these regions can modulate alcohol 
drinking behavior, we investigated the effects of both acute and chronic alcohol on 
synaptic function in vPAG DA neurons.  Briefly, we found that alcohol did not modulate 
mini inhibitory post-synaptic current (mIPSC) in vPAG DA neurons, but increased mini 
excitatory post-synaptic current (mEPSC) frequency. Consistent with these synaptic 
effects, we found that acute alcohol increased firing of vPAG DA neurons.  Interestingly, 
chronic alcohol exposure did not alter synaptic function in these neurons. 
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MATERIALS AND METHODS 
 Animals and Husbandry 
Adult male TH-eGFP Swiss Webster mice aged between 5 to 9 weeks were bred 
and used in accordance with an animal use protocol approved by the University of North 
Carolina – Chapel Hill (IACUC).  Mice were group-housed in our colony room under a 
12:12-hour light cycle, with lights on at 7:00 AM daily. Mice were given ad libitum 
access to rodent chow and water.  Mating pairs of mice were created by GENSAT and 
obtained from the Mutant Mouse Regional Resource Center in North Carolina.  In the 
TH-eGFP mouse line, the genome was modified to contain multiple copies of a modified 
BAC in which an eGFP reporter gene was inserted immediately upstream of the coding 
sequence of the gene for tyrosine hydroxylase (TH). Data presented here were obtained 
from the transgenic mice maintained in-house. 
 Electrophysiology Brain Slice Preparation and Slice Whole-Cell Electrophysiology 
Mice were decapitated under isoflurane anesthesia and their brains were rapidly 
removed and placed in ice-cold sucrose artificial cerebrospinal fluid (ACSF): (in mM) 
194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 
NaHCO3 saturated with 95% O2/5% CO2. Three hundred micron slices were prepared 
using a Leica VT1200 vibratome (Wetzlar, Germany).  Brain slices containing the PAG 
were stored at approximately 30°C in a heated, oxygenated holding chamber containing 
ACSF (in mmol/L) 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, 
and 26.0 sodium bicarbonate before being transferred to a submerged recording chamber 
maintained at approximately 30°C (Warner Instruments, Hamden, Connecticut)  
Recording electrodes (3–5 MΩ) were pulled with a Flaming-Brown Micropipette Puller 
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(Sutter Instruments, Novato, CA) using thin-walled borosilicate glass capillaries. During 
inhibitory transmission experiments, recording electrodes were filled with (in mmol/L) 
70 KCl, 65 K+-gluconate, 5 NaCl, 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, 2 QX-314, .6 EGTA, 4 ATP, .4 GTP, pH 7.4, 290 to 295 mOsmol.  During 
excitatory transmission experiments, recording electrodes were filled with (in mmol/L) 
117 D-gluconic acid, 118 CsOH, 20 HEPES, 0.4 EGTA, 5 TEA, 2 MgCl¬2, 4 Na2APT, 
0.4 Na2GPT, 2 QX-314.  To measure Ih current, cells were held at -140mV for a 1-
second duration immediately after breaking into the membrane and analyzed for the final 
100ms of this voltage step.  In voltage-clamp experiments, cells were held at −70 mV and 
inhibitory post-synaptic currents (IPSCs) were pharmacologically isolated with 3 mmol/L 
kynurenic acid, to block α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid 
(AMPA) and N-methyl-D-aspartate (NMDA) receptor-dependent post-synaptic current.  
Excitatory post-synaptic currents (EPSCs) were pharmacologically isolated by adding 25 
µmol/L picrotoxin to block γ-Aminobutyric acid (GABA) receptor-dependent current. To 
isolate miniature inhibitory post-synaptic currents (mIPSCs), tetrodotoxin (0.5 μmol/L) 
was added to the perfusing ACSF solutions described above.  During chronic intermittent 
alcohol exposure electrophysiology experiments, mini inhibitory (cells held at +10mV) 
and excitatory (cells held at -55mV) transmission was examined within the same cells 
using the following internal solution (in mmol/L): 135 Cs-Methanesulfanate, 10 KCl, 10 
HEPES, 1 MgCl2, 0.2 EGTA, 4 MgATP, 0.3 Na2GPT, 20 phosphocreatine.  In firing rate 
experiments, we used cell-attached experiments where the cell membrane was not broken 
in with the seal maintained under 50MΩ, while recording electrodes were filled with (in 
mmol/L) 135 K+-gluconate, 5 NaCl, 2 MgCl2, 10 HEPES, 0.6 EGTA, 4 Na2APT, 0.4 
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Na2GPT. Signals were acquired via a Multiclamp 700B amplifier (Molecular Devices, 
Sunnyvale, California), digitized at 20 kHz, filtered at 3 kHz, and analyzed using 
Clampfit 10.2 software (Molecular Devices). Input resistance and access resistance were 
continuously monitored during experiments. Experiments in which changes in access 
resistance were greater than 20% were not included in the data analysis. 
 Chronic Intermittent Alcohol Vapor Paradigm 
Adult mice were exposed to alcohol vapor or air in La Jolla Alcohol Research 
chambers for 16 hours per day (16 hours on, 8 hours off; from 4pm to 8am the following 
day) for 2 cycles of 4 days on, and 3 days off.  Alcohol vapor was created by bubbling 
95% alcohol in a vaporizer at a rate of 4-6 L/min air; the vapor was administered at a 
flow rate of approximately 15 L/min air to each individually sealed cage. Alcohol levels 
were adjusted to reach animal blood alcohol concentration (BAC) above 200 mg/dL, and 
monitored using a breathalyzer at the beginning and end of every exposure. To achieve 
intoxication BAC levels, alcohol-exposed mice were injected with 10ml/kg of 68.1mg/kg 
of the alcohol dehydrogenase inhibitor pyrazole combined with 1.5g/kg 20% (v/v) 
alcohol in saline; air-exposed mice received 10 ml/kg of 68.1mg/kg pyrazole in saline.  
Electrophysiology was performed 48 hours after exiting the chamber from the last cycle. 
 Immunohistochemistry 
Mice were anesthetized with Avertin and perfused trans-cardially with chilled 
0.01M phosphate buffered saline (PBS), immediately followed by 4% paraformaldehyde 
phosphate buffered saline.  Brains were extracted and post-fixed in 4% paraformaldehyde 
for 24 hours and immersed in a 30% sucrose solution for 48 hours, both at 4˚C.  Coronal 
sections 45um in thickness were collected using a Leica VT1000S vibratome (Leica 
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Microsystems, Nussloch, Germany) and stored in a 50% glycerol solution at -20˚C until 
immunohistochemistry was performed.  Slices were rinsed for 5 minutes in chilled PBS, 
followed by a 10-minute incubation in 0.1% Triton X-100 in PBS solution, two 5-minute 
PBS washes, and a 30-minute incubation in 0.5% Triton X-100 in PBS solution. After a 
1-hour incubation in a blocking solution made of 0.1% Triton X-100/10% Normal 
Donkey Serum in PBS, the tissue was then incubated for 48 hours at 4°C with their 
respective primary antibodies diluted in 0.1% Triton X-100/10% Normal Donkey Serum 
in PBS blocking solution (anti-Tyrosine Hydroxylase, [1:500], Pel-Freez P60101-0, Lot 
28632; anti-Green Fluorescent Protein, [1:500], Aves Laboratories, GFP-1020). Slices 
were rinsed three times for 10 minutes in chilled PBS before incubating for 24 hours at 
4°C in their respective secondary antibodies diluted in PBS (Alexa Fluor 647 Donkey 
anti-Sheep, [1:800], TH; Alexa Fluor 488 Donkey anti-Chicken, [1:200], GFP; Jackson 
Immuno Research).  Tissue was rinsed four times for 10 minutes in chilled PBS, and 
mounted using Vecta-Shield Mounting Medium (Vector Laboratories, Burlingame, CA, 
H-1000) prior to image collection. 
Statistics 
Effects of drugs during electrophysiological recordings were evaluated by 
comparing the magnitude of the dependent measure (mIPSC or mEPSC frequency and 
amplitude) between the baseline and wash-on (when drug had reached maximal effect at 
10 minutes) periods using paired Student’s t-tests. The effects of antagonists/blockers on 
the ability of drugs to modulate synaptic transmission were compared using t-tests during 
the washout period. All values given for drug effects throughout the article are presented 
as mean ± SEM.  
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RESULTS 
Basal Electrophysiology Properties:  vPAG vs. VTA 
We first wanted to confirm that the TH-eGFP mouse line would report correctly 
for DA neurons in the vPAG.  To examine this, we performed dual label 
immunofluorescence and looked for overlap of TH and eGFP in the vPAG of the reporter 
(Fig2.1).    We found that 69.6±4.5% of eGFP positive neurons were co-localized withTH 
(n =2 animals). Having determined the fidelity of this TH-eGFP reporter line for DA 
neurons in the vPAG, we then examined the membrane capacitance and resistance in 
eGFP-positive neurons in the vPAG.   
We used whole-cell voltage clamp to examine the Ih current, membrane 
capacitance, and membrane resistance in eGFP-positive neurons in both the vPAG and 
the well-characterized VTA.  We found that the A10 DA neuron population in the VTA 
had a significantly (Student’s t-test, p < 0.0001) lower membrane resistance (194.8 ± 
52.9MΩ, n=10) compared to the A10dc DA neurons in the vPAG (866.7±72.5 MΩ, 
n=36)(Fig2.2B).  Further, the DA neurons in the VTA also displayed a significantly (p < 
0.0001) larger membrane capacitance (56.4±5.2 pF) than DA neurons in the vPAG 
(16.6±1.0pF) (Fig2.2A).  Having established these differences in basic membrane 
properties, we next sought to determine whether the DA neurons in the PAG exhibit a 
hyperpolarization-activated current (Ih current).  The presence of Ih current has been 
used as a marker for DA neurons in the VTA (247), however, this has been a topic of 
intense scrutiny (248).  Consistent with previous findings, we found that putative DA 
eGFP-positive neurons in the VTA displayed a robust Ih current (-172.5± 46.3 pA, 
n=10), similar to those observed in previous studies (249).  In contrast, the dopamine 
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neurons in the vPAG had a significantly smaller Ih current (-8.1±2.4 pA, n=36) (Fig2.2C 
and D), with most neurons in the vPAG lacking any measurable hyperpolarization 
current. 
Acute alcohol modulation of GABAergic transmission in the vPAG 
We next evaluated the effects of 50mM alcohol on GABAergic synaptic 
transmission.  We selected a concentration based on previous studies that showed 
effective modulation of inhibitory currents in the VTA (250, 251).  We found no effects 
(n=6) on miniature IPSC (mIPSC) frequency (100.4±27.6% of baseline. Fig2.3B), 
amplitude (85.4±17.0% of baseline, Fig2.3C), or decay (98.4±4.7% of baseline, 
Fig2.3D).  Further, acute alcohol had no effects on evoked IPSC transmission (data not 
shown).  Our data suggest that synaptic GABAergic transmission in vPAG DA neurons is 
not modulated by alcohol.  However, previous studies have shown that alcohol can 
potently modulate extra-synaptic GABAA receptors (116).  Thus, we examined the 
impact of 50 mM alcohol on holding current and the standard deviation of the noise, two 
measures that are related to tonic GABAA receptor-mediated currents (116).  We found 
that 50 mM alcohol does not alter the holding current or cause a shift in the noise 
(Fig2.3E), suggesting that neither synaptic nor extra-synaptic GABAergic transmission 
are modulated by acute alcohol in the vPAG. As recent studies have found that the 
actions of alcohol on dopamine neurons can depend on intact network function (252), we 
next assessed the ability of alcohol to modulate spontaneous GABAergic transmission.  
In these experiments, GABAergic transmission was isolated by pharmacologically 
blocking glutamatergic transmission with 3mM kynurenic acid, but tetrodotoxin was 
excluded from the bath solution to allow for action potential dependent network activity.  
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We found that 10-minute bath application of 50mM alcohol (n=10) significantly (p<0.05) 
decreased the amplitude (88.7±15.5% of baseline. Fig2.4D) of spontaneous inhibitory 
post-synaptic current (sIPSC), but had no effect on frequency (87.3±42.2%. Fig2.4C). 
Acute alcohol modulation of miniature excitatory post-synaptic current in the vPAG 
Having established that acute alcohol had minimal effects on inhibitory inputs to 
vPAG DA neurons, we next examined the impact of acute alcohol on excitatory 
glutamatergic synaptic function. We found that a 10-minute bath application of 50mM 
alcohol (n=7) significantly (p=0.02) increased mEPSC frequency (144.9±17.7% of 
baseline. Fig2.5C), but had no effects on amplitude (93.3±4.6% of baseline, Fig2.5D).  
Interestingly, this effect did not appear to reverse over the course of the 10-minute 
washout.  Taken together, these results demonstrate that alcohol has no effects on 
inhibitory inputs, but facilitates excitatory inputs onto vPAG dopamine neurons via a 
presynaptic mechanism.  
Acute alcohol modulation of vPAG dopamine neuron cell firing rate 
After finding minimal effects of acute alcohol on inhibitory synaptic inputs but an 
increase in excitatory synaptic inputs, we investigated the effects of alcohol on overall 
firing rate using the loose cell-attached recording configuration.  In these experiments, we 
did not block any synaptic transmission, and thus assessed the impact of alcohol on the 
circuits that regulate vPAG DA neuron firing.  We found that the average firing rate of 
the last 5 minutes of the 10-minute 50mM alcohol (2.5Hz±0.6, n=7. Fig2.6B,C)  bath 
application is significantly (p=0.04) higher (32.6%±10.1 increase) when compared to 
baseline (2.0Hz±0.5. Fig2.6A).  This effect was not reversible with a 15-minute washout, 
similar to our data in mEPSCs.  In addition, alcohol application had no significant effects 
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(n=7. Fig2.6D) on firing rate in the presence of the excitatory AMPA receptor antagonist 
NBQX (10uM).  These results suggest that acute alcohol increases the firing of vPAG 
DA neurons via an enhancement of excitatory inputs. 
Chronic intermittent alcohol vapor exposure modulation of synaptic transmission in the 
vPAG 
Having found that acute alcohol could enhance glutamatergic drive onto vPAG 
DA neurons, we next investigated the effects of chronic intermittent vapor alcohol 
exposure on both the mini inhibitory and mini excitatory inputs onto vPAG dopamine 
neurons.  It has been previously shown that 2 cycles of chronic intermittent alcohol vapor 
exposure has both behavioral and electrophysiological effects.  Specifically, mice 
undergoing this exposure paradigm exhibit enhanced alcohol seeking behavior (253, 254), 
as well as altered plasticity in the BNST (255, 256), a target of vPAG DA neurons.  We 
recorded both mIPSC and mEPSC transmission within the same cell and compared the 
frequency, amplitude, and excitatory/inhibitory (E/I) ratio between air-exposed animals 
(n=8) and alcohol exposed animals (n=7).  Surprisingly, our results showed no 
differences in basal frequency (Fig2.7C), amplitude (Fig2.7D), and E/I ratio (Fig2.7E) 
between control and alcohol groups.  In addition, we examined basal cell properties (data 
not shown) of both groups and found no difference in membrane capacitance, resistance, 
and holding potential.   Taken together, these results suggest that two weeks of chronic 
alcohol vapor does not alter the basal synaptic properties of vPAG DA neurons at this 
time point. 
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DISCUSSION 
How alcohol modulates neurochemically-defined neurons in distinct brain regions 
is crucial to understanding alcohol’s effects on behavior.  This study focused on 
determining the actions of alcohol on a population of DA neurons in the vPAG that have 
been implicated in a wide variety of behaviors.  We identified dopamine neurons using 
the TH-eGFP transgenic mouse line and found approximately 70% of GFP-positive cells 
were co-labeled with TH.  While there is a concern for over-reporting, it is also a 
possibility that some GFP-positive cells express TH at levels that are too low to be 
observed through the immunofluorescent techniques.  Further, it is critical to note that a 
recent paper from the Ungless group showed similar results (257).  Having confirmed the 
fidelity of this reporter, we then characterized vPAG dopamine neuron membrane 
properties.  Interestingly, we observed little to no hyperpolarization-activated currents, 
similar to what was observed in a recent study (257).  Historically, researchers have used 
the presence of Ih current to identify dopamine neurons in the VTA (179, 258-260).  
While some studies were unable to establish a consistent relationship between 
dopaminergic neurons and Ih currents (248), other studies have suggested that the 
magnitude of the Ih current varies with target projection areas, as well as sub-regions of 
DA neuron-populated sites (179, 260).  Recent studies have found dopamine neurons 
located in the medial portion of the VTA that display small Ih currents (261), similar to 
our results in vPAG dopamine neurons.  Given the physiological and anatomical 
similarities between these populations of neurons, it is possible that they play similar 
roles in alcohol and stress-related behaviors.  Indeed, preliminary results from our group 
suggest that similar to the neurons in the medial VTA, the TH-neurons in the vPAG also 
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express vGlut2.  Future studies using optogenetic approaches will more clearly examine 
this interesting possibility.  
Having characterized the basic properties of vPAG dopamine neurons, we next 
evaluated the effects of alcohol on synaptic transmission.  We found that concentrations 
of bath-applied alcohol that had previously been shown to increase GABA release in the 
VTA, had no effect on mIPSCs on vPAG dopamine neurons.  Our result contrasts with 
previous studies from the VTA that have demonstrated alcohol can enhance both 
spontaneous and miniature GABA transmission (251, 252).  The ability of alcohol to 
enhance GABA transmission in the VTA, however, appears to depend on the sub region 
of the VTA, with anterior-VTA DA neurons showing an alcohol-induced increase in 
GABA transmission and posterior-VTA DA neurons showing a reduction in spontaneous 
but not miniature GABA transmission (252).  Thus, our results demonstrating a lack of 
alcohol effects on mIPSCs in the vPAG are similar to posterior VTA DA neurons.  
Following this, we investigated how alcohol might impact extra-synaptic receptors.  
Curiously, we found that 50 mM alcohol did not alter holding current of these neurons, 
suggesting a lack of effect on extra-synaptic currents.  While we did not see evidence for 
a modulation here, this could be due to the exquisite sensitivity of extra-synaptic 
receptors for alcohol.  However, in a series of pilot experiments, we examined the ability 
of THIP, a compound that can selectively activate extra-synaptic receptors, to modulate 
holding current in vPAG DA neurons and found no effect, suggesting that these neurons 
do not express these receptors.  Because of the lack of effect on mini IPSCs and holding 
current, we investigated the effect of alcohol on spontaneous IPSCs, as it was shown in 
the posterior VTA that alcohol significantly reduced sIPSCs.  We found similar results as 
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Guan et al., that alcohol caused a significant but minimal decrease in spontaneous 
inhibitory transmission; however, the decrease in amplitude we observed appears less 
robust than the effect in the posterior VTA.  This could be due to some differences in 
effects of alcohol on the surrounding network and inputs.  Taken together, these results 
suggest that vPAG DA neurons could be similarly modulated by alcohol as the posterior 
VTA DA neurons, and may have a partially overlapping set of GABA inputs, either from 
local interneurons or distal projections such as the BNST and the central amygdala. 
We next examined the effects of alcohol on excitatory glutamatergic inputs in 
vPAG dopamine neurons.  We found that bath application of alcohol increased mEPSC 
frequency, with no effect on amplitude, suggesting an increase in glutamate release.   
Numerous studies have shown that acute alcohol decreases glutamatergic transmission in 
many brain regions implicated in alcohol abuse, such as the central nucleus of the 
amygdala (CeA) (120).    The ability  of acute alcohol to enhance glutamatergic 
transmission in the vPAG was strikingly  similar to that found in the VTA , where 
dopamine signaling mediates the enhancement of glutamatergic input by alcohol (262). 
Our observation of alcohol having minimal inhibitory effects on GABAergic inputs but 
an enhancement in glutamatergic transmission led us to investigate alcohol’s effects on 
overall firing rate.  We found an increase in firing rate upon application of acute alcohol, 
with this alcohol effect diminished in the presence of NBQX, suggesting this increase in 
firing rate is AMPA receptor-dependent.  Taken together with our previous data, we 
speculate that via these alterations in function, acute alcohol may lead to increased 
dopamine release in the terminal regions, such as the BNST.  This is interesting, as DA 
signaling in the BNST can modulate alcohol drinking behavior (237, 263).  
 35 
To further investigate the role alcohol plays in modulating vPAG dopamine 
neurons and their target regions, we examined the synaptic effects of chronic intermittent 
alcohol vapor exposure for 2 cycles.  This paradigm has been shown to enhance the 
development of long-term potentiation in the BNST, via modulation of the excitatory 
NMDA receptors extra-synaptically (255), as well as modulation of CRF-dependent 
increase of sEPSCs in the BNST (256).  Given the knowledge that chronic alcohol 
modulates synapses and functions in the BNST, one of the extended amygdala structures 
that interact with the vPAG and impact behaviors critical to alcohol addiction, our 
findings were surprising.  We found no effects of chronic intermittent alcohol exposure 
on either the inhibitory or excitatory inputs in the vPAG dopamine neurons.  Perhaps a 
more profound systemic insult than the 2 cycles of intermittent alcohol exposure 
presented is required to affect the synaptic functions and to produce a detectable network 
effect.  While considering the possibility that the 2-cycle vapor alcohol exposure 
paradigm could impact synaptic alterations differentially in a strain-dependent manner, it 
is interesting to note that during alcohol exposure, the Swiss Webster mice used in these 
experiments displayed a robust behavioral alteration towards aggression. Alternatively, it 
is possible that there are alterations in transmitter release in downstream regions such as 
the BNST that would engage CRF signaling leading to the alterations in function (256).  
While our study focused on changes in synaptic transmission, it is also possible that 
chronic alcohol is altering expression of neuromodulatory receptors in the BNST.  
Chronic alcohol exposure has been shown to alter opioid peptides in the vPAG (264), as 
well as in other brain regions that interact with the vPAG (265).  This is interesting, as 
opioids have been shown to influence alcohol related behaviors (214, 266, 267).  Thus, 
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although a direct network effect was not observed, chronic intermittent alcohol exposure 
could have an impact on modulatory peptides in the vPAG and how they regulate 
synaptic transmission.   
It is currently unclear how alcohol modulation of vPAG DA neurons alters 
behavior.  Given the prominent role that the vPAG plays in sleep and pain processing, it 
is tempting to speculate that alcohol actions on this circuit are involved in these processes. 
Future studies utilizing optogenetics to probe pathway-defined plasticity, as well as 
applying designer receptors exclusively activated by designer drugs (DREADD) to 
characterize pathway and cell type-specific modulation will likely shed light on this 
exciting possibility. 
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CONCLUSIONS 
Here, we characterized the cell membrane properties as well as effects of alcohol 
exposure on vPAG DA neurons.  Acute alcohol enhanced glutamate inputs and had 
inhibitory effects on GABA inputs, resulting in a net increase in firing rate.  Chronic 
intermittent alcohol vapor exposure had no effects on GABA or glutamate transmission 
onto the vPAG dopamine neurons.  Taken together, these results add to the growing body 
of literature pointing towards discrete effects of alcohol on defined cell-types in the brain. 
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FIGURES AND TABLES 
 
Figure 2.1:  The tyrosine hydroxylase-eGFP transgenic mouse model identifies 
dopamine neurons via fluorescence in the vPAG.  (A) Immunohistochemistry can be used 
to label and verify validity of the reporter via (1) tyrosine hydroxylase fluorescence, (2) 
eGFP fluorescence, and the (3) co-localization of eGFP and tyrosine hydroxylase in dual-
positive cells.  No significant Ih current was observed in vPAG DA neurons (B) (1) eGFP 
and tyrosine hydroxylase-positive cells can be visualized under the microscope to 
selectively record from.  Staining showed that the recorded cells loaded with (2) 
neurobiotin via diffusion from the patching pipette, are (3) tyrosine hydroxylase-positive. 
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Figure 2.2:  The dopamine neurons in the VTA and in the vPAG display different 
electrophysiological membrane properties.  (A) vPAG dopamine neurons have 
significantly lower membrane capacitance (p < 0.0001) than VTA dopamine neurons.  
(B) vPAG dopamine neurons have significantly higher membrane resistance (p < 0.0001) 
than VTA dopamine neurons.  (C), (D) vPAG dopamine neurons display little to no 
hyperpolarization current (Ih) comparing to VTA dopamine neurons. 
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Figure 2.3:  Acute bath-applied alcohol had no effect on mini inhibitory post synaptic 
currents (mIPSCs) in vPAG dopamine neurons.  (A) Representative mIPSC traces of 
baseline control (i) and after 10 minutes of alcohol wash-on (ii). (B) Acute alcohol had no 
effect on mIPSC frequency. (C) Acute alcohol had no effects on mIPSC amplitude. (D) 
Acute alcohol had no effect on mIPSC decay. (E) Acute alcohol had no effect on mIPSC 
noise. 
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Figure 2.4:  Acute bath-applied alcohol had no effects on spontaneous inhibitory post 
synaptic current (sIPSC) frequency in vPAG dopamine neurons.  Representative sIPSC 
traces of (A) baseline control and (B) after 10 minutes of alcohol wash-on. (C) Acute 
alcohol had no effects on sIPSC frequency. (D) Acute alcohol significantly decreased 
sIPSC amplitude. 
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Figure 2.5:  Acute bath-applied alcohol increased mini excitatory post synaptic currents 
(mEPSCs) in vPAG dopamine neurons.  (A) Representative mEPSC trace of baseline 
control. (B) Representative mEPSC trace after 10 minutes of alcohol wash-on. (C) Acute 
alcohol increased mEPSC frequency. (D) Acute alcohol had no effects on mEPSC 
amplitude. 
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Figure 2.6:  Acute bath-applied alcohol (50mM) increased firing rate of vPAG dopamine 
neurons in the cell-attached recording configuration.  (A) Representative firing rate trace 
of baseline control. (B) Representative firing rate trace in the same neuron after 10 
minutes of alcohol wash-on. (C) Alcohol increased firing rate in vPAG DA neurons.  (D) 
Alcohol had no significant effect on firing rate in the presence of NBQX (10µM). 
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Figure 2.7:  Chronic intermittent alcohol vapor exposure did not affect inhibitory and 
excitatory synaptic properties.  (A) Representative mEPSC trace. (B) Representative 
mIPSC trace.  (C) Chronic intermittent alcohol had no effect on mini frequency. (D) 
Chronic intermittent alcohol had no effect on mini amplitude. (E) Chronic intermittent 
alcohol had no effect on mini excitatory/inhibitory transmission ratio.
 CHAPTER 3. MODULATION OF KAPPA OPIOID RECEPTORS ON 
VPAG DOPAMINE NEURONS 
INTRODUCTION 
The mesolimbic dopamine circuit has been well-characterized in reward and drug 
addiction; it includes dopaminergic projections from the VTA to the nucleus accumbens, 
and the nigrostriatal pathway projecting from the substantia nigra to the stiratum.  
However, recent studies (38) have suggested the involvement of another mid-brain 
population of dopamine neurons that is highly implicated in the rewarding properties of 
drug addiction, as well as the negative emotional behaviors that often accompany 
withdrawal.  The A10dc group DA neurons project from the ventral periaqueductal gray 
(vPAG) to the extended amygdala - the bed nucleus of stria terminalis (BNST) and the 
central amygdala (CeA), areas known to regulate stress- and anxiety-related behaviors.  
In addition, the vPAG has been implicated in arousal and several negative emotional 
behaviors such as anxiety (241, 242, 268), ethanol withdrawal (56, 57, 269), fear 
conditioning and extinction (270-274), sleep (46), and pain (244, 245, 275, 276). These 
behavioral studies raise the possibility that functions of vPAG DA neurons may play a 
role in the negative affective state associated with drug abuse that often leads to relapse 
(84).   
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The PAG is a heterogeneous region in cell types, as well as in its projection 
targets implicated in various behaviors.  For instance, the projection from the PAG to the 
prefrontal cortex (46), hypothalamus (73), and the dorsal raphe (46) has been shown to 
modulate sleeping behavior.  Projections to the pons regulate cardiovascular and 
respiratory functions (277); projections to the hypothalamus regulate cardiovascular 
functions (52), as well as defense and fear conditioning (278); it as well as projects to the 
rostral ventral medulla that regulates nociception (279).  Despite the large body of studies 
that have investigated PAG projections and functions, few have demonstrated cell-type 
specific properties.  In this study, we took advantage of transgenic mouse lines, to 
specifically target vPAG dopamine neurons to examine how their synaptic transmission 
is modulated.   
The following section describes some behaviors tightly linked to PAG activity, 
and vPAG dopamine signaling has been shown to mediate these behaviors.  Of particular 
interest, the vPAG dopamine seems to regulate an array of negative emotional behaviors.  
Recent studies suggest that the vPAG dopamine projects to the BNST, where dopamine 
and corticotropin-releasing factor (CRF) interacts to regulate fear and anxiety (38).  
Modulation in the vPAG has also been shown to influence emotional behavior where 
antagonism of the GABA receptors in the vPAG increases anxiety-like behavior (39).  
Further, the sensitization of vPAG has been shown to suppress positive affect in rats (40).  
While nociception and negative emotional behaviors seem to exacerbate one another (43-
45), studies show that the ventral PAG is also an important site in the ascending 
nociceptive control (ANC) pathway, projecting to the rostral ventral medulla (41).  There 
is evidence that dopamine neurons in the PAG may potentially play a role in the ANC as 
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opiate anti-nociception is attenuated upon chemical lesion of vPAG dopamine neurons 
(42), also suggesting a role of dopamine signaling in the mediation of opioid actions in 
the vPAG.  Another PAG dopamine-mediated behavior heavily linked to negative 
emotional state is sleep, as sleep deprivation has been shown link to stress (47), anxiety 
(48), and depression (49).  Evidence illustrated the critical role of PAG dopamine 
projections to the prefrontal cortex in sleeping behavior, as selective chemical lesion of 
dopamine neurons in the PAG leads to increase in sleep time (46).  These studies show 
that the vPAG DA signaling is heavily engaged in negative affect, which overlaps with 
those behaviors previously identified to encourage drug relapse.   
As mentioned in chapter I, dopamine signaling has been closely associated with 
the rewarding properties of drugs of abuse, and the kappa opioid receptor activity can 
modulate drinking behavior, as well as negative emotions.  Kappa opioid receptor (KOR) 
activation mediates aversive effects produced by alcohol challenge (213), and systemic 
antagonism of KOR also attenuates dependence-induced excessive ethanol self-
administration in rats (214).  It would also seem like KOR systems can modulate 
dopamine mediated reward-seeking behavior, as acute KOR activation decreases the 
rewarding properties of alcohol (215) while decreasing operant responding to ethanol 
(215).  Together, these studies demonstrated that the kappa opioid receptor (KOR) system 
plays a critical role in negative emotional disorders, as well as drug abuse, possibility via 
the modulation of dopamine signaling.   
Dysphoria induced by KOR activation includes depression (198), stress and 
anxiety-like behaviors (199, 200), and most importantly, drug abuse-induced depressive-
like behaviors (201).  Many of the KOR-relevant behaviors have been shown to be 
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modulated in mid brain regions such as the VTA, vPAG, and dorsal raphe.  In particular, 
dopamine signaling seems to play a critical role in these negative affective disorders.  
Studies have shown that KOR activation in the dorsal raphe, also containing A10dc 
dopamine neurons just ventral of the vPAG, produces conditioned place aversion (202), 
mediates the aversive effects of stress, and reinstates drug-seeking (182).  Further, anti-
nociception induced by oxytocin can be blocked by KOR antagonism in the PAG (204).  
Understanding of the mechanisms underlying KOR’s effects on behavior in the PAG will 
allow us to better adapt strategies while seeking treatment for negative mood disorders 
and drug addiction.  Mechanistically, it has been shown that kappa opioid receptor 
activation has the ability to modulate dopaminergic neurons in the VTA.  More 
specifically, a KOR agonist inhibits the VTA DA neurons projecting to the prefrontal 
cortex (192).  Interestingly, while isolating GABA-mediated inhibitory post-synaptic 
currents (IPSCs) in the VTA dopamine neurons, the same research group found that 
opioid agonists inhibited GABAergic transmission.  GABAergic neurons have been 
shown to inhibit projection dopamine neurons in other dopamine-rich brain regions such 
as the VTA (67).    Similar to the VTA, a population of tonically-active GABAergic 
neurons have been found in the PAG (66). Although KORs have been shown to distribute 
widely in the PAG (205), specific dopamine neuron-modulation has yet to be investigated 
due to the heterogeneity of the PAG.  Given the strong implications of the vPAG in both 
negative affect and drug addiction, the existing behavioral and electrophysiological 
findings together lead us to the hypothesis that kappa opioid receptors could serve a role 
in modulating GABAergic inputs on the dopaminergic neurons in the vPAG.   
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Physiologically, the activation of receptors of the opioid family putatively inhibits 
presynaptic transmission.  Opioid receptor-activation inhibits glutamate transmission 
presynaptic to neurons in the hypothalamus (181), as well as presynaptic to the brainstem 
catecholamine neurons (280).  Opioid receptor-activation has also been shown to 
presynaptically inhibit GABAergic transmission in the VTA, resulting in disinhibition of 
the VTA dopamine neurons, increasing their activity (67, 281).  The above evidence 
raises the possibility that kappa opioid receptor activation could modulate vPAG 
dopamine neurons, as well as the activities of their output regions.  With the knowledge 
that vPAG DA neurons project to the BNST that regulates stress and negative affect, 
understanding of kappa modulation on these neurons could provide insight onto the 
regulation of emotional behaviors.  In this study, we utilized a tyrosine hydroxylase 
(TH)-eGFP transgenic mouse to selectively record from DA neurons in the vPAG and 
pharmacologically evaluated the impact and mechanisms of KOR activation on GABA-
mediated inhibitory inputs onto vPAG dopamine neurons. 
As a member of the opioid receptor family, kappa opioid receptor actions have 
been shown to play important roles in analgesia, mood modulation, and addiction (198-
201, 282).  The KORs are widely spread throughout the brain, spinal cord, and peripheral 
systems, and are activated endogenously via the opioid peptide dynorphin (173, 175, 283, 
284).  KOR-activation involves the inhibition of cyclic AMP production (285), mediated 
through the coupling of the inhibitory G-protein Gi/o (286) (Fig3.1).  Dissociation of the 
α subunit recruits beta arrestin and activates downstream mitogen-activated protein 
(MAP) kinases such as ERK1/2 (287) and p38 that affect transcription factor expression.  
The βγ subunits has been shown to directly bind and inhibit calcium channel, as well as 
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increase potassium channel conductance (175).  These direct effects on ion channel 
conductance have been found in several brain regions, ranging from the hippocampus to 
the dorsal root ganglia (288), In addition, the phosphorylated KOR activates ERK1/2, as 
well as phosphoinositide 3 (PI3) kinase and protein kinase A (PKA).  Evidence suggests 
ERK signaling mediates KOR activation-induced attenuation in evoked IPSC response in 
the BNST (178).  In addition, studies have shown that p38 signaling mediates the effects 
of KOR-induced conditioned place preference, and is required for negative affective 
behaviors that can be blocked by KOR antagonists (289).  In the peripheral nervous 
system, KOR has been shown to inhibit inflammatory analgesia via the PI3 Kinase 
signaling pathway (290).  These results suggest an array of possible downstream 
signaling cascades upon KOR activation.  Therefore, in this study, we used 
pharmacological manipulations to investigate downstream KOR signaling cascade 
through which the presynaptic inhibition was mediated. 
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MATERIALS AND METHODS 
Animals and Husbandry 
Adult male TH-eGFP mice on a Swiss Webster background (aged between 5 to 9 
weeks) were bred and used in accordance with an animal use protocol approved by the 
University of North Carolina – Chapel Hill (IACUC). Mice were group-housed in our 
colony room under a 12:12- hour light cycle, with lights on at 7:00 AM daily. Mice were 
given ad libitum access to rodent chow and water. Mating pairs of mice were created by 
GENSAT and obtained from the Mutant Mouse Regional Resource Center in North 
Carolina. In the TH-eGFP mouse line, the genome was modified to contain multiple 
copies of a modified BAC in which an eGFP reporter gene was inserted immediately 
upstream of the coding sequence of the gene for tyrosine hydroxylase (TH). Data 
presented here were obtained from the transgenic mice maintained in-house. 
Electrophysiology Brain Slice Preparation 
Mice were decapitated under isoflurane anesthesia and their brains were rapidly 
removed and placed in ice-cold sucrose artificial cerebrospinal fluid (ACSF): (in mM) 
194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 
NaHCO3 saturated with 95% O2/5% CO2. Three hundred micron slices were prepared 
using a Leica VT1200 vibratome (Wetzlar, Germany). 
Slice Whole-Cell Electrophysiology 
Brain slices containing PAG were obtained and stored at approximately 30°C in a 
heated, oxygenated holding chamber containing artificial cerebrospinal fluid (ACSF) (in 
mmol/L) 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0 
sodium bicarbonate before being transferred to a submerged recording chamber 
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maintained at approximately 30°C (Warner Instruments, Hamden, Connecticut) 
Recording electrodes (3–5 MΩ) were pulled with a Flaming-Brown Micropipette Puller 
(Sutter Instruments, Novato, CA), using thin-walled borosilicate glass capillaries. During 
inhibitory transmission experiments, recording electrodes were filled with (in mmol/L) 
70 KCl, 65 K+-gluconate, 5 NaCl, 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, 2 QX-314, .6 EGTA, 4 ATP, .4 GTP, pH 7.4, 290 to 295 mOsmol.  In experiments 
where post-synaptic GPCR signaling was blocked, GDPβs was used to replace GTP in 
the internal solution.  All experiment were conducted under the voltage clamp 
configuration, cells were held at −70 mV and inhibitory post-synaptic currents (IPSCs) 
were pharmacologically isolated with 3 mmol/L kynurenic acid, to block α-amino-3- 
hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) and N-methyl-D-aspartate 
(NMDA) receptor-dependent post-synaptic current. To isolate miniature inhibitory post-
synaptic currents (mIPSCs), tetrodotoxin (0.5 μmol/L) was added to the perfusing ACSF 
solutions described above.  Signals were acquired via a Multiclamp 700B amplifier 
(Molecular Devices, Sunnyvale, California), digitized at 20 kHz, filtered at 3 kHz, and 
analyzed using Clampfit 10.2 software (Molecular Devices). Input resistance and access 
resistance were continuously monitored during experiments. Experiments in which 
changes in access resistance were greater than 20% were not included in the data 
analysis. 
Statistics 
Effects of drugs during electrophysiological recordings were evaluated by 
comparing the magnitude of the dependent measure (mIPSC frequency and amplitude) 
between the baseline and wash-on (when drug had reached maximal effect at 10 minutes) 
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periods using paired Students t-tests. The effects of antagonists/blockers on the ability of 
drugs to modulate synaptic transmission were compared using t-tests during the washout 
period. All values given for drug effects throughout the article are presented as mean ± 
SEM. 
Drugs 
Dynorphin A (300 nM) and Norbinaltorphimine (Nor-BNI, 100 nM) were from 
Tocris (Ellisville, MO), and were both dissolved in distilled water. BAPTA-AM (50µM), 
Gallein (100µM), and Wortmannin (1µM) were from Tocris and dissolved in DMSO.  
Nor-BNI is an opioid receptor antagonist highly selective for the kappa opioid receptor 
(3);  4-[4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]pyridine 
(SB203580, 20 µM) and 4-aminopyridine (4-AP, 100µM) were from Ascent and 
dissolved in distilled water; alpha-[Amino[(4-aminophenyl)thio]methylene]-2-
(trifluoromethyl)benzeneacetonitrile (SL327, 10 µM) was from Ascent and dissolved in 
DMSO. Tetrodotoxin citrate (TTX, 500nM) and kynurenic acid (3mM) were from 
Abcam and dissolved in water.  GDPβs (4mM) and RP-Adenosine 3’,5’-cyclic 
monophophorothioate triethylammonium salt hydrate (RP-camps, 10µM) were from 
Sigma-Aldrich and dissolved in water. EGTA (100µM) was obtained from Fisher 
Scientific and dissolved in 1M NaOH. 
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RESULTS 
Endogenous KOR agonist Dynorphin A attenuates GABAergic input onto vPAG DA 
neurons via presynaptic mechanisms 
We first examined the effects of KOR activation on GABA synaptic transmission 
via bath application of the endogenous ligand dynorphin A (300nM).  A 10-minute bath 
application of dynorphin A significantly attenuated the mini inhibitory post-synaptic 
current (mIPSC) in the vPAG dopamine neurons (Fig3.2A, n=5).  Specifically, a decrease 
was seen in mIPSC frequency (69.5±7.4% of baseline, p=0.03, Fig3.2B,D), but not 
amplitude (99.3±4.8% of baseline, Fig3.2C,E), indicating the possibility of a pre-synaptic 
mechanism.  To further confirm that the dynorphin effect observed was mediated through 
KOR activation, we incubated the slices in a selective KOR antagonist, nor-BNI (100nM) 
for 40 min before and during dynorphin wash-on (n=5). In the presence of nor-BNI, 
dynorphin A application failed to produce effects on mIPSC frequency (93.3±10.3% of 
baseline, Fig3.2F) or amplitude (89.4±6.1% of baseline, Fig3.2G).  To assess the level of 
tonic KOR functions, we investigated the effects of nor-BNI alone (n=6) and found no 
effects in sIPSC frequency (100.3±5.2% of baseline, Fig3.2H) and amplitude (84.8±7.7% 
of baseline, Fig3.2I), suggesting that there is no tonic level of KOR activation in the 
vPAG DA neurons.  These mini data suggest a pre-synaptic effect of dynorphin in the 
vPAG DA neurons.  We further tested this by blocking post-synaptic GPCR functions via 
the replacement of GTP with GDPβs in the recording pipette, which disrupts the 
exchange of GTP and GDP, thus interfere with the downstream signaling cascade upon 
GPCR activation.  With post-synaptic GPCR functions impaired, the application of 
dynorphin A still decreased mIPSC frequency (54.7±5.8% of baseline, n=6, p=0.04, 
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Fig3.3A,C), but not amplitude (97.8±11.3% of baseline, Fig3.3B, D), providing 
additional support  that dynorphin attenuates inhibitory input onto vPAG DA neurons via 
a pre-synaptic mechanism.  Unpublished results from the Kash lab have shown GDPβs 
effective in blocking the postsynaptic effects of a NPY Y1 agonist (Leu-pro NPY) in the 
BNST. 
Dynorphin effects on GABA are not mediated through MAP kinase signaling 
We next investigate the role of MAP kinases ERK1/2 and p38 in KOR 
modulation of GABAergic transmission.  As mentioned earlier, ERK1/2 antagonist has 
been shown to mediate KOR activation-induced attenuation in evoked IPSC response in 
the BNST (178).  We incubated the slices in either a selective MEK inhibitor (SL327, 10 
µM, n=6), or p38 inhibitor (SB203580, 20 µM, n=5) for 40 min before and during 
dynorphin wash-on.  In the presence of the MEK inhibitor SL327, dynorphin A 
significantly decreased mIPSC frequency (67.2±10.6% of baseline, p=0.04, Fig3.4A), but 
not amplitude (97.1±4.3% of baseline); In the presence of the p38 inhibitor SB203580, 
dynorphin A significantly decreased mIPSC frequency (46.6±9.9% of baseline, p<0.05, 
Fig3.4B) and amplitude (83.2±3.6% of baseline, p=0.02, Fig3.4B).  Together, these 
results suggest that the dynorphin-induced attenuation of GABAergic input onto vPAG 
DA neurons was not mediated through MAP kinase signaling. 
Dynorphin effects on GABA are not mediated through calcium and potassium ion 
channel conductance 
As mentioned earlier, the dissociation of the βγ subunit of the GPCR can directly 
influence the conductance of ion channels.  Thus, we investigated the roles calcium and 
potassium channels play in the dynorphin modulation of GABA-mediated IPSC.  To 
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eliminate the role of calcium channels, we incubated the slices in calcium-free ACSF and 
the selective calcium chelators BAPTA-AM (50µM) and EGTA (100µM) for 1-2 hours 
before recording, and continued to record from the slice in calcium-free ACSF in the 
presence of just EGTA, or EGTA plus 4-AP (100µM) to block potassium channels.  In 
calcium-free experiments, dynorphin A significantly decreased mIPSC frequency 
(71.9±8.6% of baseline, p=0.02, n=6, Fig3.5A), but not amplitude (102.3±9.6% of 
baseline, Fig3.5A).  In calcium-free experiments where potassium channels were blocked 
with 4-AP, dynorphin A significantly decreased mIPSC frequency (77.8±8.0% of 
baseline, p<0.05, n=8, Fig3.5B), but not amplitude (107.5±5.7% of baseline, Fig3.5B).  
These data suggest that the change in conductance of these ion channels does not mediate 
the KOR activation effect on IPSCs.  To further investigate the role of KOR βγ subunits, 
we incubated the slices in gallein (100µM), an inhibitor of G protein βγ subunit-
dependent signaling.  The KOR activation-induced attenuation of GABA transmission 
was blocked in the presence of gallein (n=6), with no significant difference in mIPSC 
frequency (107.1±7.1% of baseline, Fig3.5C) or amplitude (102.8±7.4% of baseline, 
Fig3.5C).  Together these data suggest that the effects of KOR on GABAergic 
transmission were mediated via βγ subunit signaling, but not the ion channels.  
Dynorphin effects on GABA are not mediated through PI3 kinase or PKA signaling 
Having established the possibility of βγ-mediation of KOR-induced decrease in 
GABA function, we further investigated other possibilities of KOR activation, the PI3 
kinase and PKA signaling.  We incubated the slices in the PI3 kinase inhibitor 
wortmannin (1µM), or the PKA inhibitor RP-camps (10µM), wortmannin did not block 
the previously observed decrease in GABA transmission frequency (72.4±7.1% of 
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baseline, n=6, Fig3.6A), and no effects on amplitude remains (94.2±5.7% of baseline, 
Fig3.6B).  RP-camps did not block the KOR-induced decrease in GABA transmission; 
Dynorphin frequency (73.0±7.0% of baseline, n=5, p=0.051, Fig3.6B) was lower than 
baseline with no effects on amplitude (89.8±6.1% of baseline, Fig4B).  These data 
suggest that PI3 kinase and PKA do not mediate KOR activation-induced decrease in 
GABA function. 
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DISCUSSION 
Ventral PAG dopamine neurons have been implicated in a variety of emotional 
behaviors.  How these mid-brain dopamine neurons are modulated by kappa opioid 
functions could be a crucial piece of information in understanding the regulation of 
addiction, as well as the associated negative affect that often leads to relapse.  This study 
focused on determining the effects of kappa opioid receptor-activation on the inhibitory 
synaptic transmission onto vPAG dopamine neurons, in addition, the downstream 
signaling mechanisms through which the effects take place.   
We frist investigated the effects of KOR activation on GABA-mediated mini 
IPSC and found that KOR activation by its endogenous ligand dynorphin A attenuated 
inhibitory transmission by frequency but not amplitude, suggesting a presynaptic 
mechanism-mediation.  This KOR effect is consistent with previous studies in the BNST 
(178), and was blocked in the presence of a KOR antagonist nor-BNI in both regions, 
suggesting KOR-selective mediation.  Although all vPAG DA neurons recorded in this 
study showed a decrease in GABA-mediated IPSCs, studies in the VTA demonstrated 
that KOR attenuates inhibitory transmission onto dopamine neurons in a projection 
target-dependent manner (179, 291).  Recent evidence showed that GABA afferent 
region could also play a role in the differential modulation of IPSC by KOR activation 
(292).  Interestingly, KOR antagonist nor-BNI alone had no effects on spontaneous 
inhibitory transmission, implying no tonic constitutive kappa modulation on vPAG DA 
neurons.  In order to verify that the attenuation on GABAergic transmission was indeed 
mediated by presynaptic signaling of KOR, and not postsynaptic, we blocked GPCR 
signaling in the recorded postsynaptic cell.  The blockade of postsynaptic GPCR was 
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achieved by the addition of GDPβs in the patching pipette, filling the recorded cell by 
diffusion.  GDPβs is a non-hydrolyzable GDP analogue; it blocks postsynaptic GPCR 
signaling by preventing the exchange of GDP to GTP, thus preventing G protein 
activation.  We found that the attenuation of mIPSCs caused by dynohpin A persisted in 
the presence of postsynaptic GDPβs, suggesting that the postsynaptic KOR does not play 
a role in the effects seen.  Using GDPβs to block postsynaptic GPCRs has been shown 
effective in the Kash lab where postsynaptic NPY Y1 receptor agonist effects were 
blocked in its presence.  The above evidence demonstrated KOR mediates inhibitory 
inputs onto vPAG DA neurons presynaptically.  This is not surprising as KOR agonists 
have been shown to inhibit presynaptic GABA release in other brain regions, such as the 
BNST (178), and in the hypothalamus (293).   
We next investigated the downstream signaling cascade that mediates the KOR 
activation-induced attenuation of IPSCs in vPAG DA neurons.  Previous studies in the 
Kash lab demonstrated in the BNST that KOR-induced decrease in GABAergic current 
was mediated presynaptically via the classic MAP kinase ERK1/2 pathway.  In this study, 
the blockade of ERK1/2 signaling by inhibitors U0126 and SL327 both blocked the KOR 
effects on GABAergic transmission that was previously seen.  However, the current 
investigation showed that inhibition of ERK1/2 signaling via SL327 did not block 
dynorphin-induced decrease in GABAergic transmission, suggesting site-specific actions 
of KOR activation-triggered ERK1/2 signaling in the inhibition of presynaptic GABA.  
No previous study has shown a correlation between the MAP kinase P38 and modulation 
of synaptic transmission.  However, is it a possible target as studies have shown it critical 
in KOR-mediated behaviors such as stress, reinstatement of drug-seeking, and dysphoria 
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(182, 289).  We hypothesized KOR activation attenuates inhibitory transmission input, 
allowing dopamine neuron activity to be enhanced, increasing in signaling in projection 
areas such as the BNST and amygdala to increase anxiety- and stress-like behaviors, 
making p38 a likely candidate for the attribution of decreased inhibition.  However, in the 
presence of the p38 inhibitor SB203580, diminished GABAergic current persisted.  
Curiously, both mIPSC frequency and amplitude decreased upon application of the KOR 
agonist dynorphin A, implying perhaps SB203580 modulated postsynaptic properties that 
makes vPAG dopamine neurons sensitive to dynorphin A.  
We then examined ion channels that are directly regulated by the βγ subunit of the 
KOR.  Opioids depress transmission at many central synapses (294); many studies have 
implicated an kappa opioid-mediated inhibition of presynaptic calcium channels (189, 
295) or the activation of presynaptic potassium channels (296, 297).  However, other 
studies have ruled out the involvement of either channel (181, 291, 298).  Our data 
demonstrated that in the vPAG dopamine neurons, neither of these ion channels 
contributed to the presynaptic inhibition of GABAergic release.  However, inhibition of 
G protein βγ subunit-dependent signaling successfully prevented dynorphin-induced 
decrease in mIPSC frequency, suggesting that other actions of the βγ subunit can 
contribute to this effect.  Because gallein has been shown to not only inhibit βγ subunit, 
but also activate PI3 kinase activity (299), we sought to clarify the role of PI3 kinase with 
wortmannin, a PI3 kinase inhibitor.  Our results suggested that KOR-induced reduction of 
presynaptic inhibition lies outside of the actions of PI3 kinase.  Together, we have 
confirmed that KOR-activation reduces inhibitory input via a presynaptic mechanism.  In 
addition, with the removal of calcium, the effect persists, indicating that this inhibition 
 61 
occurs downstream of calcium entry and is calcium-independent.  These results raise the 
possibility that dynorphin A could be activating the KOR and directly affect the 
presynaptic release machinery in the GABAergic inputs onto the vPAG dopamine 
neurons.  This data is similar to studies on KOR presynaptic inhibition of glutamatergic 
inputs in the hypothalamus (181).  Although we did not identify the molecular target 
through which dynorphin inhibits presynaptic GABA, our results are consistent with 
studies proposing direct modulation of the exocytosis release machinery by the βγ subunit 
of the Gi/o-coupled GPCR (300, 301).  In addition, we continued to rule out the 
possibility of the actions of phosphorylated KOR, inhibiting PKA and the generation of 
cAMP.  We found a close to significant (p=0.051) decrease in mIPSC frequency upon the 
application of dynorphin A, consistent with other results that suggest KOR does not 
inhibit through that actions of PKA.   
In this current study, we found that KOR activation presynaptically attenuates 
inhibitory inputs potentially via the modulation of release machinery.  However, KOR 
influences on excitatory inputs of vPAG dopamine neurons are unclear.  Some studies 
have shown the KOR does not modulate EPSCs onto other dopamine-rich regions, such 
as the VTA (302) while others have shown the opposite (303).  over all cell excitability in 
the VTA has been shown to be modulated in a projection-specific manner (192) where 
only mPFC-projecting VTA dopamine neurons are hyperpolarized by KOR activation, 
but not NAc-projecting dopamine neurons.  It is currently unclear how KOR modulation 
of vPAG DA neurons alters behavior.  Given the prominent role that the vPAG plays in 
pain and negative affect processing, as well as the correlation of KOR functions and 
emotional behaviors, it is tempting to speculate that KOR actions on this circuit are 
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involved in these processes.  Under the hypothesis that KOR presynaptically inhibits 
GABAergic inputs, disinhibiting the vPAG dopamine neurons to potentially modulate 
projection areas and related behaviors, further elucidation is needed regarding how the 
KOR modulates the glutamatergic inputs, as well as the overall effect on activity of the 
vPAG DA neurons.  Future studies utilizing optogenetics to probe pathway-defined 
plasticity, as well as applying designer receptors exclusively activated by designer drugs 
(DREADD) to characterize pathway and cell type-specific modulation will likely shed 
light on this exciting possibility. 
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FIGURES AND TABLES 
 
Figure 3.1:  KOR-mediated signal transduction.  Receptor activation by a KOR-selective 
ligand can result in activation of several kinase cascades.  Arrows refer to activation 
steps, T line refer to blockers or inhibition of functions.  Abbreviations are as follows: α, 
G-protein alpha subunit; βγ, G-protein beta-gamma subunit; cAMP, cyclic adenosine 
monophosphate; ERK1/2, extra-cellular signal-regulated kinase; GRK3, G-protein 
coupled receptor kinase3; JNK, c-Jun N-terminal Kinase; p38, p38 MAPK; p, 
phosphorylation;PI3K, phosphoinositol 3-kinase; PKCζ, protein kinase C zeta. 
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Figure 3.2:  KOR agonist, dynorphin A (300nM), decreases mIPSCs in vPAG DA 
neurons via KOR actions. (A) Representative mIPSC traces of baseline control (i) and 
after 10 minutes of 300nM dynorphin A wash-on (ii).  (B) Dynorphin A significantly 
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decreased mIPSC frequency.  (C) Dynorphin A had no effect on mIPSC amplitude.  (D) 
Cumulative frequency of mIPSC was shifted towards longer interevent intervals by 
Dynorphin A.  (E) Cumulative probability of mIPSC amplitude was not affected by 
dynrophin A.  (F) Dynorphin A no longer decreased mIPSC frequency in the presence of 
nor-BNI (100nM).  (G) Dynorphin A had no effect on mIPSC amplitude in the presence 
of nor-BNI. (H) nor-BNI alone had no effect on mIPSC frequency.  (I) nor-BNI alone 
had no effect on mIPSC amplitude. 
 
 
 
 
  
 66 
 
Figure 3.3:  The postsynaptic GPCR inhibitor, GDPβs (4mM), defused into the recorded 
vPAG DA neuron did not block dynorphin A from attenuating mIPSC, suggesting a 
presynaptic mechanism.  (A) Inhibition of postsynaptic GPCR did not block dynorphin A 
from attenuating mIPSC frequency.  (B) Dynorphin A had no effects on mIPSC 
amplitude in the presence of GDPβs. (C) GDPβs did not block dynorphin A’s ability to 
shift the mIPSC cumulative frequency towards longer interevent intervals.  (D) 
Dynorphin A had no effect on mIPSC amplitude cumulative probability.  
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Figure 3.4:  The ERK1/2 inhibitor SL327 (10 µM) and the p38 inhibitor SB203580 (20 
µM) did not block dynorphin A from attenuating mIPSC.  (A) Dynorphin A significantly 
decreased mIPSC frequency in the presence of SL327.  (B) Dynorphin A had no effects 
on mIPSC amplitude in the presence of SL327.  (C) Dynorphin A significantly decreased 
mIPSC frequency in the presence of SB203580. (D) Dynorphin A significantly decreased 
mIPSC amplitude in the presence of SB203580. 
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Figure 3.5:  KOR inhibition does not require calcium and potassium ion channels.  The 
GPCR βγ subunit inhibitor blocked dynorphin A from attenuating mIPSC.  (A) 
KOR/dynorphin A inhibition persisted even when all Ca
2+
 was removed by incubating 
slices in 0mM Ca
2+
/4mM Mg
2+
, 100µM EGTA with 50µM BAPTA-AM. (B) 
KOR/dynorphin A inhibition persisted even when all Ca
2+
 was removed  and K
+
 channels 
are blocked with 4AP (100µM). (C) Gallein (100µM) prevented dynorphin A from 
inhibiting mIPSC frequency. mIPSC amplitude remained unaffected.  
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Figure 3.6:  The PI3 kinase inhibitor wortmannin (1µM) and the PKA inhibitor RP-
camps (10µM) did not block dynorphin A from attenuating mIPSC.  (A) Dynorphin A 
significantly decreased mIPSC frequency but had no effect on amplitude in the presence 
of wortmannin.  (B) Dynorphin A decreased mIPSC frequency and had no effect on 
amplitude in the presence of RP-camps. 
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Figure 3.7: KOR presynaptically inhibit GABA release potentially via the disruption of 
functions in SNARE complex of the release machinery by the βγ subunit of the KOR 
GPCR.  
 
 CHAPTER 4. VPAG DOPAMINE MODULATION ON PROJECTION 
AREA AND ITS BEHAVIORAL IMPLICATIONS 
INTRODUCTION 
Previous studies in the Kash lab have shown that both acute alcohol and KOR 
activation can modulate the synaptic transmission onto vPAG DA neurons; and these 
neurons have been implicated in the negative emotional behaviors contributing to drug 
relapse (84, 87, 88).  Specifically, acute alcohol increased vPAG DA neuron firing rate 
via an increase in excitatory mEPSC, while it had no effect on inhibitory mIPSC (Chapter 
2).  In addition, we showed that the activation of KOR by its endogenous ligand 
dynorphin A significantly decreased mIPSC measured in the vPAG DA neurons, via the 
presynaptic actions of the βγ subunit of the KOR GPCR, potentially through altering the 
functions of the release machinery (Chapter 3).  While both alcohol exposure and KOR 
activation have been shown to produce negative emotional behaviors that contribute to 
the relapse of alcohol use, the potential of an alteration in vPAG DA neuron activity to 
modulate the synaptic transmission of projection regions has yet to be addressed.  Both 
the VTA and vPAG dopamine neurons have been shown to project to the stress center, 
the BNST (38, 304, 305).  Previously, we demonstrated distinct differences in 
physiological membrane properties of these two populations of dopamine neurons 
(Chapter 2).  Specifically, the vPAG DA neurons displayed significantly lower 
 72 
membrane capacitance and significantly higher resistance.  In addition, the commonly 
observed hyperpolarization-activated Ih current in the VTA DA neurons was not observed 
in the vPAG DA neurons.  Based on these differences in cell properties, these two 
distinct groups of DA neurons could potentially modulate activity in the projection region 
differentially. 
Previous studies have shown that dopamine from the VTA to the BNST leads to a 
CRF-dependent increase in glutamate release in the BNST (256, 304), while dopamine 
signaling in the BNST has been suggested to be involved in the regulation of anxiety-like 
behaviors in a potential CRF-dependent fashion (38).  This indirect effect on 
glutamatergic transmission in projection areas indicates that dopamine signaling has the 
potential of modulating the excitability of projection areas.  In addition, the VTA 
dopamine projection terminals co-release dopamine and glutamate in the nucleus 
accumbens (261, 306).  These findings raised a possibility that activity of the vPAG DA 
neurons could serve also as an excitatory input to target regions, such as the BNST.  
Interestingly, other studies have suggested that dopamine neurons could also express 
GABA as co-transmitters.  Specifically, activation of dopaminergic neurons in the striatal 
slices rapidly inhibited action potentials in both the direct and indirect pathway via the 
release of GABA (307).  However, the ability of vPAG dopamine neurons to co-release 
excitatory or inhibitory transmitters has not been assessed, nor is its ability to modulate 
target regions known.  In this study, we used viral approaches to address how vPAG DA 
neurons can modulate target regions.  Recent technique development allows researchers 
to simultaneously address both cell type-specificity and projection-specificity while 
examining neural networks and their behavioral implications.  This study utilized two 
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cutting edge chemical genetic tools – optogenetics and designer receptors exclusively 
activated by designer drugs (DREADD), to address the modulatory role of the vPAG 
dopamine neurons in the BNST. 
Optogenetics utilizes light-sensitive proteins found in algae and bacteria to 
activate or inhibit neural activity.  The follow three types of proteins provide activation 
and inhibition in sub-second time scale and are most commonly incorporated: the neural-
activating cation channel channelrhodopsin-2 (ChR2) (308, 309), the neural-inhibiting 
halorhodopsin (NpHR) (310, 311), the neural-silencing proton pump archaerhodopsin 
(Arch) (312).  These proteins change the excitability of cells by regulating membrane 
potential according to their protein properties, and are activated by exposure to light of 
different wavelengths.  In neurons, a large current is required to depolarize the cell to 
trigger an action potential, thus functional ChR2 must be expressed at a high level in 
order to reach a cumulative current large enough to reach action potential.  Such a high 
density expression can be achieved via the infection of an adeno-associated virus (AAV).  
In vivo studies have demonstrated effective control of activation or inhibition of neural 
networks, as well as behavior, via optogenetics (313). 
In addition to the light-sensitive ion channels, the Designer receptors exclusively 
activated by designer drugs (DREADDs) are modified G-protein coupled receptors 
(GPCRs) that have no basal constitutive activity, and respond to a synthetic ligand that 
had no natural targets within the organism.  The DREADD can be coupled with the 
modified human muscarinic receptors (M1-M4) to activate the inhibitory Gαi and the 
stimulatory Gαq and Gαs (314-316) .  These receptors are activated via a synthetic ligand, 
the pharmacologically inert metabolite of clozapine, clozapine-N-oxide (CNO).  CNO 
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demonstrated the lack of appreciable affinity to any receptor but the modified hM1D-
hM4D (316).  In addition, studies have shown that not only can CNO activate Gα 
signaling; the activation of downstream signaling pathways that involve multiple 
effectors is also preserved in the modified human muscarinic DREADD receptors, such 
as β-arrestin and downstream MAP kinase signaling (315).   
Both optogenetic light-activated cation channels and DREADDs are packaged as 
cre-inducible viral constructs and are expressed in specific cell populations via transgenic 
Cre mouse lines.  In this study, we used the tyrosine hydroxylase-cre (TH-cre) and 
vesicular glutamate transporter 2 (vGlut2-cre) mouse lines to specifically express ChR2 
or DREADD with a fluorophore for the identification and activation of dopamine neurons 
and glutamatergic neurons in the vPAG.  We hypothesize that vPAG DA neuron 
activation can lead to excitation of BNST neurons and their signaling.  
  
 75 
MATERIALS AND METHODS 
Animals and Husbandry 
Adult male TH-cre mice on a C57 (aged between 5 to 9 weeks) were bred and 
used in accordance with an animal use protocol approved by the University of North 
Carolina – Chapel Hill (IACUC). Mice were group-housed in our colony room under a 
12:12- hour light cycle, with lights on at 7:00 AM daily. Mice were given ad libitum 
access to rodent chow and water. Mating pairs of mice were purchased from The Jackson 
Laboratory. In the TH-cre male mouse line, the tyrosine hydroxylase (TH) promoter 
directs expression of Cre recombinase to catecholaminergic cells; in the vesicular 
glutamate transporter 2 (vGlut2-cre) mouse line, the vGlut2 transporter promoter directs 
expression of Cre recombinase to a subset of glutamatergic neurons. Data presented here 
were obtained from the transgenic mice maintained in-house. 
Immunohistochemistry 
Mice were anesthetized with Avertin and perfused trans-cardially with chilled 
0.01M phosphate buffered saline (PBS), immediately followed by 4% paraformaldehyde 
phosphate buffered saline. Brains were extracted and post-fixed in 4% paraformaldehyde 
for 24 hours and immersed in a 30% sucrose solution for 48 hours, both at 4˚C. Coronal 
sections 45um in thickness were collected using a Leica VT1000S vibratome (Leica 
Microsystems, Nussloch, Germany) and stored in a 50% glycerol solution at -20˚C until 
immunohistochemistry was performed.  Slices were rinsed four times for 5 minutes in 
chilled PBS, followed by a 30-minute incubation in 50% methanol, a 5- minute 
incubation in 3% hydrogen peroxide, three 10-minute PBS washes, a 30-minute 
incubation in 0.5% Triton X-100 in PBS solution, and a 10-minute PBS wash. After a 1-
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hour incubation in a blocking solution made of 0.1% Triton X-100/10% Normal Donkey 
Serum in PBS, the tissue was then incubated overnight (~18 hours) at room temperature 
with their respective primary antibodies diluted in 0.1% Triton X-100/10% Normal 
Donkey Serum in PBS blocking solution (anti-Tyrosine Hydroxylase, [1:1000], 
Immunostar 22941-907001; anti-Green Fluorescent Protein, [1:500], Aves Laboratories, 
GFP-1020). Slices were rinsed three times for 10 minutes in chilled PBS before 
incubating for 2 hours in their respective secondary antibodies diluted in PBS (Alexa 
Fluor 647 Donkey anti-Mouse, [1:200], TH; Alexa Fluor 488 Donkey anti-Chicken, 
[1:200], GFP; Jackson Immuno Research). Tissue was rinsed four times for 10 minutes in 
chilled PBS, and mounted using Vecta-Shield Mounting Medium (Vector Laboratories, 
Burlingame, CA, H-1000) prior to image collection. 
Stereotaxic Surgery 
Mice were anesthetized with isoflurane and placed in a stereotaxic frame (Kopf 
Instruments, Tujunga, CA). A microinjection needle (32 gauge) connected to a 1μL 
Hamilton syringe mounted onto a digital micro-infusion pump (KD Scientific, Holliston, 
MA) was inserted at a 20˚ angle to aim for the vPAG (coordinates from Bregma: -4.5 AP, 
0.0 ML, -2.8 DV).  Dopaminergic neurons were transduced with 250nL of AAV5 virus 
coding for double floxed inverted ChR2(H134R)-mcherry under control of the EF1α 
promoter, mixed with 250nL of AAV8 virus coding for double floxed inverted 
hM3D(Gq) DREADD-IRES-mCitrine driven by the human synapsin (hSYN) promoter at 
a rate of 0.1µL/min followed by 5 minutes to allow diffusion of viral particles away from 
the injection site.  Mice were allowed to recover for 3-4 weeks to achieve maximal 
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infection and protein expression before DREADD behavioral assays, and 4-6 weeks prior 
to electrophysiological experiments. 
Viral vectors 
DNA plasmids coding double floxed-ChR2-mcherry were obtained from the 
laboratory of Karl Deisseroth. Plasmid DNA were grown and collected using a standard 
plasmid maxiprep kit (Qiagen, Hilden, Germany). Following plasmid purification and 
restriction digest, and sequencing to assure DNA fidelity, purified AAV was produced, 
using calcium phosphate precipitation methods by the UNC Vector Core facilities (AAV 
serotype 2; University of North Carolina at Chapel Hill). Viral titers used were > 1012 
g.c. (genome copies) /mL.  DREADD virus was obtained from Dr. Bryan Roth at UNC-
Chapel Hill, who developed the construct. 
Electrophysiology Brain Slice Preparation 
Mice were decapitated under isoflurane anesthesia and their brains were rapidly 
removed and placed in ice-cold sucrose artificial cerebrospinal fluid (ACSF): (in mM) 
194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 
NaHCO3 saturated with 95% O2/5% CO2. Three hundred micron slices were prepared 
using a Leica VT1200 vibratome (Wetzlar, Germany). 
Slice Whole-Cell Electrophysiology 
Brain slices containing the vPAG were obtained and stored at approximately 30°C 
in a heated, oxygenated holding chamber containing artificial cerebrospinal fluid (ACSF) 
(in mmol/L) 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 
26.0 sodium bicarbonate before being transferred to a submerged recording chamber 
maintained at approximately 30°C (Warner Instruments, Hamden, Connecticut)  
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Recording electrodes (3–5 MΩ) were pulled with a Flaming-Brown Micropipette Puller 
(Sutter Instruments, Novato, CA) using thin-walled borosilicate glass capillaries.  In 
vPAG light-evoked firing experiments, light pulses of 2ms were introduced at varying 
frequencies of 1, 5, 10, 20, and 40Hz.  We used cell-attached experiments where the cell 
membrane was not broken in with the seal maintained under 50MΩ, while recording 
electrodes were filled with (in mmol/L) 135 K+-gluconate, 5 NaCl, 2 MgCl2, 10 HEPES, 
0.6 EGTA, 4 Na2APT, 0.4 Na2GPT.  During BNST light-evoked GABAergic and 
glutamatergic electrophysiology experiments, inhibitory (cells held at +10mV) and 
excitatory (cells held at -55mV) transmission was examined using the following internal 
solution (in mmol/L): 135 Cs-Methanesulfanate, 10 KCl, 10 HEPES, 1 MgCl2, 0.2 
EGTA, 4 MgATP, 0.3 Na2GPT, 20 phosphocreatine.  Signals were acquired via a 
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, California), digitized at 20 
kHz, filtered at 3 kHz, and analyzed using Clampfit 10.2 software (Molecular Devices). 
Input resistance and access resistance were continuously monitored during experiments. 
Experiments in which changes in access resistance were greater than 20% were not 
included in the data analysis. 
Behavioral Assays 
Ten Mice injected with Gq DREADD were allowed 5 weeks for transfection (5 
TH-cre, 5 wild type).  The following behavioral assays were conducted with 1 resting day 
in between each assay: Von Frey hyperalgesia, open field test, elevated plus maze test, 
and light/dark box test.  On each test day, each mouse was weighed and injected with 
CNO (1mg/kg) 30 minutes before the start of behavioral session. 
Von Frey hyperalgesia 
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Ten Mice injected with Gq DREADD were allowed 5 weeks for transfection (5 
TH-cre, 5 wild type).  Starting day 1 of habituation, mice were weighed and injected with 
saline 30 minutes prior to being placed individually into plexiglass cages on a wire-mesh 
table positioned approximately 1 ft above a standard laboratory bench. Animals were 
given approximately 25 min to acclimate to the testing apparatus.  Three hyperalgesia test 
habituation days were allow prior to 2 baseline days and 1 CNO-injected (1mg/kg) test 
day.  During the hyperalgesia test, the monofilament was placed perpendicularly onto the 
midplantar region of the left and right hind paws through the holes in the wire-mesh 
table, and pressure was applied just until the point of deflection of the monofilament, 
after which the monofilament was immediately removed.  A von Frey monofilament 
(Stoelting, Wood Dale, IL)  with a calibrated bending force of 1.4g was presented to the 
hind paw 10 times, with a 1 s duration and a 1 s inter-stimulus interval for each 
presentation. The percent responses to the frequency test were calculated as the # paw 
withdrawals/10.  Mechanical hyperalgesia was defined as an increase in the response rate, 
since this monofilament does produce some withdrawal behavior in normal mice.  The 
results of the left and right paw did not differ, thus, we averaged the response of both 
paws of the five animals in each condition. 
Open field test 
Mice were placed into the corner of an open field box measuring 20”x20” for a 
30-minute session.  The center and surrounding space of the open field box were 
physically identical, but defined during analysis.  Time spent in each defined space and 
total distance traveled were tracked with the software EthoVision XT by Noldus.  The 
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center space was defined by the 50% area in the center, and the other 50% area accounted 
for the surrounding space.   
Elevated plus maze test 
Mice were placed onto the center of the elevated plus maze facing an open arm 
for a 5-minute session.  The maze consisted of 2 open arms and 2 closed arms, each 
measuring 13.5”x2.5”.  Time spent in each compartment and entry number were analyzed 
with the software EthoVision XT by Noldus. 
Light/dark box test 
Mice were placed into the dark half of the Light/Dark box for a 15–minute 
session, with each compartment measuring 11”x5”.  The light half of the chamber was 
illuminated with LED lights to reach a brightness of 400 lux, while the dark side was 
maintained at nearly 0 lux.  Time spent and entry number in each compartment were 
analyzed with the software EthoVision XT by Noldus. 
Statistics 
Effects of behavioral assays were evaluated by comparing the parameters 
mentioned above between the wild type and TH-cre animals using unpaired Student’s t-
tests.  All values given for behavioral effects throughout the article are presented as mean 
± SEM. 
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RESULTS 
vPAG dopamine neurons and their projection to the BNST 
We first aimed to confirm the prior studies that found that vPAG DA neurons 
project to the BNST.  To examine this, we injected the retrograde tracer fluorogold (FG) 
into the BNST and allowed ten days for the uptake and trafficking by neuronal terminals 
prior to perfusing the animals for tissue.  TH was stained for in coronal sections from the 
vPAG and VTA.  We found co-localization of TH and FG in both sites (Fig4.1A-B), 
indicating that dopamine neurons in these regions indeed project to the BNST.  As 
mentioned earlier, dopamine neurons in the VTA have been shown to co-express 
glutamate.  To characterize the dopamine neurons in the vPAG, we stained for TH and 
GFP in a vGlut2-ai3 mouse line and found that while only a small subset of vGlut2-
positive neurons co-expressed TH, nearly all dopamine neurons were also vGlut2-
positive (Fig4.1C-D).  In addition, a TH-cre mousseline injected with an AAV5-DIO-
eYFP cre-inducible virus, images from the BNST revealed that vPAG DA neurons 
appear to project to a sub-region of the dorsal BNST that highly resembles the oval 
nucleus (Fig4.1E).  Some striatal dopamine neurons have been shown to co-express 
GABA, thus we assess this possibility in the vPAG using a GAD67-eGFP mouse line to 
satin for TH.  We found that GABAergic neurons are located laterally and distinct from 
the TH-positive dopamine neurons (Fig4.2). 
Optogenetics – vGlut2-cre animals 
Next we used an optogenetic approach to assess the potential of vPAG DA 
neurons to modulate activity in the BSNT.  We first used vGlut2-cre mice, as we 
reasoned that this would be a more robust projection, and would allow us to assess the 
 82 
feasibility of this approach.  In a vGlut2-cre mousseline, we injected AAV-DIO-ChR2-
mCherry into the vPAG and allowed 8 weeks for transfection.  Transfected cell bodies in 
the vPAG that expressed mcherry were visualized and recorded from.  Blue light 
stimulation pulses (2ms each) varying in frequency were presented, we found that the 
vPAG dopamine neurons fired in a time-locked manner at corresponding frequencies of 
1, 5, 10, 20, and 40Hz (Fig4.3), indicating a successful and functional ChR2 transfection.  
To assess the ability of vPAG DA neurons to modulate BNST transmission, we targeted 
BNST neurons in proximity to clusters of mCherry-expressing terminals and attempted to 
light-activate ChR2-expressing terminals.  Blue light stimulation pulses were presented in 
the same fashion as were in the vPAG.  We measured light-evoked glutamatergic currents 
in the BNST neurons (n=4) at corresponding frequencies of 1, 5, 10, 20, and 40Hz 
(Fig4.4), indicating vPAG DA neuron-activation can trigger glutamate release in the 
projected BNST.  Interestingly, on occasions, we also found light-evoked GABAergic 
currents (n=2) with a longer delay between stimulation artifact and current onset 
(11.5±4.9ms) comparing to that of the light-evoked glutamate current (2.115±0.16ms). 
Optogenetics – TH-cre animals 
Using the same approach as the above section, TH-cre animals were injected with 
AAV-DIO-ChR2-mCherry into the vPAG and allowed 8 weeks for transfection.  We 
targeted BNST neurons in proximity to clusters of mCherry-expressing terminals and 
attempted to light-activate ChR2-expressing terminals.  Blue light stimulation pulses 
(2ms each) were presented in pairs and measured light-evoked GABAergic and 
glutamatergic currents.  We found measureable light-evoked glutamatergic currents 
(Fig4.5B) in the BNST (n=3).  Interestingly, we also found light-evoked GABAergic 
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currents (n=5) (Fig4.5A) in some BNST neurons.  Similar to the findings in vGlut2-cre 
virus-injected animals, the GABA currents have a significant longer delay between 
stimulation artifact and current onset (8.0±1.3ms) comparing to that of the light-evoked 
glutamate current (3.1±0.2ms)  
Von Frey hyperalgesia test  
We next evaluated the behavior implications of the vPAG DA neurons in 
nociception.  We used a Von Frey filament that produced around 60-70% paw-
withdrawal response out of the ten filament stimulations given.  The data of the right foot 
and left foot were pooled together as they were not different.  We found that during the 
two baseline days, the responses of the two groups were not different (Baseline day1: 
TH-cre 6.2±0.3, WT 6.3±0.4; baseline day2: TH-cre 6.2±0.3, WT 6.3±0.4, Fig4.6).  On 
the CNO injection day, both groups received injections of 1mg/kg CNO.  The TH-cre 
animals displayed a robust decrease in response (TH-cre 3.0±0.3, WT 7.1±0.3), 
indicating a robust anti-nociceptive effect of activated vPAG DA neurons via Gq-
DREADD. 
Open field test 
To evaluate anxiety-like behaviors, we next conducted the open field test upon 
DREADD activation of vPAG DA neurons.  We found no significant difference in 
locomoter defined by total distance moved between wild type (9769.4±302.6cm, 
Fig4.7A) and TH-cre (8607.1±815.3cm) animals.    In addition, we found no significant 
differences in time spent in center (WT 167.6±24.7s, TH-cre 201.1±42.8s, Fig4.7B) and 
entrance number to center (WT 72.8±4.5, TH-cre 73.8±12.9, Fig4.7C), suggesting no 
change in anxiety-like behavior. 
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Elevated plus maze test 
We next conducted another anxiety assay using the elevated plus maze.  We 
found no significant differences in time spent in either open arms (WT 54.8±7.3s, TH-cre 
57.8±2.2s, Fig4.8A) or closed arms (WT 187.0±6.7s, TH-cre 193.1±2.8s, Fig4.8C).   We 
also found no significant differences in entry number to either open arms (WT 9.4±1.5, 
TH-cre 10.6±0.7, Fig4.8B) or closed arms (WT 20.0±1.1, TH-cre 22.0±2.0, Fig4.8D), 
suggesting no change in anxiety-like behavior. 
Light/dark box test 
We additionally tested anxiety using the light/dark box assay.  We found no 
significant differences in time spent in either light (WT 240.7±67.3s, TH-cre 
374.2±32.6s, Fig4.8A) or dark compartment (WT 646.7±67.9s, TH-cre 513.0±33.1s, 
Fig4.8C).   We also found no significant differences in entry number to either light (WT 
23.8±5.6, TH-cre 26±2.8, Fig4.8B) or dark compartment (WT 25.6±5.0, TH-cre 
27.2±3.1, Fig4.8D), suggesting no change in anxiety-like behavior. 
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DISCUSSION 
The vPAG DA neurons project to extended amygdala nuclei that are identified to 
regulate negative emotions such as stress and anxiety.  However, whether vPAG DA 
activities can modulate synaptic transmission in these projection regions is unknown.  
This study focused on the potential synaptic modulation of the BNST, a known projection 
area of the vPAG DA neurons, upon activation of the cell bodies in the vPAG.  First, we 
confirmed dopaminergic projections to the BNST via the injection of a retrograde tracer 
into the BNST.  We found that both VTA and the vPAG dopamine neurons project to the 
BNST, consistent with previous findings (38).  Once this projection was established, we 
next probed the possibility of vPAG dopamine neurons co-expressing vGlut2 via 
immunohistochemistry in a vGlut2 reporter mouse line stained for TH.  We found that 
nearly all of vPAG dopamine neurons also expressed vGlut2, similar to results from other 
studies showing co-expression of TH and vGlut2 in the VTA axons and synapses via 
immunocytochemical labeling (317).  Further, at the VTA projection terminals, dopamine 
neurons co-release dopamine and glutamate in the nucleus accumbens (261, 306).  These 
findings raised a possibility that activity of the vPAG DA neurons could serve also as an 
excitatory input to target regions, such as the BNST.  Interestingly, other studies have 
suggested that dopamine neurons could also express GABA as co-transmitters.  
Specifically, activation of dopaminergic neurons in the striatal slices rapidly inhibited 
action potentials in both the direct and indirect pathway via the release of GABA (307).  
This release was shown to be directly from dopaminergic axons, independent of the 
vesicular GABA transporter vGAT.  Instead, GABA was released via the vesicular 
monoamine transporter vMAT2.  In our vGAT reporter line stained for TH, vPAG 
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displayed a clear distribution of GABAergic and TH-positive dopaminergic neurons, 
distinctly separated from one another, proposing that the dopamine neurons co-express 
glutamate, but not GABA. 
We further showed that these vGlut2/DA neurons project to the stress center – 
BNST, suggesting a potential modulatory role of vPAG DA neurons in the regulation of 
negative stress affect.  In addition, our BNST vGlut2 staining highly overlapped with a 
sub-region known as the oval nucleus (Allen Brain Atlas), where dopamine signaling has 
been linked with cocaine self-administrating behavior (318).  As mentioned in earlier 
chapters, activities in the vPAG are linked to the negative affect of drug addiction, as 
well as the rewarding properties of drugs of abuse, increasing the likelihood that the 
vPAG DA neurons modulate these behaviors through signaling in the oval nucleus of the 
BNST.  Our results raised the possibility that the activation of vPAG DA neuron 
projection could positively modulate activities in the BNST by releasing glutamate. 
We next utilized both TH-cre and vGlut2-cre mouse lines with channelrhodopsin 
viral vector injected into the vPAG to identify and record from dopamine neurons in the 
vPAG.  We were able to visualize dopamine cell bodies that are transfected with the virus 
and expressing the fluorophore mCherry.  Using cell-attached recording, we 
demonstrated the success of functional ChR2 transfection that can be activated by light.  
While measuring cell firing, vPAG DA neurons fired in a time-locked manner as the 
presentation of the blue light-stimulation pulses were varied in frequency.  The 
confirmation of excitability of vPAG DA neurons triggered by blue light suggested that 
activity in ChR2-expressing processes and terminals should as well be capable of being 
stimulated for release by blue light presentations.  Indeed, while targeting BNST neurons 
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in close proximity to clusters of terminals and axonal processes expressing mCherry, we 
measured time-locked EPSC stimulation by blue light pulses.  This response was 
consistently abolished in the presence of the AMPA receptor blocker NBQX, 
demonstrating light-evoked glutamate release onto the recorded BNST neurons synapsing 
with excited vPAG DA projections.     
On occasions, we observed light-evoked GABAergic current in BNST neurons.  
However, there seemed to be a significant delay between light stimulation artifact and the 
GABAergic current measured compared to the light-evoked glutamatergic currents 
measured.  A possible explanation for this observation is that vPAG DA/vGlut2 neurons 
synapses onto local GABAergic interneurons, while light stimulation isn’t spatially 
specific, the light-evoked inhibitory input could be elicited from local interneurons.  Via 
ultra-violate uncaging of glutamate, a recent study in the BNST demonstrated a dense 
intra-regional connection that is mostly GABAergic (319).  This information compels 
more investigation on the differential distribution of DA projections onto the BNST from 
the VTA and vPAG, as well as the cell types on which they synapse.  It has been 
suggested that BNST-projecting VTA dopamine neurons release dopamine into the 
BNST, enhancing local CRF activity to modulate BNST projection neurons (256).  
Additional, other studies suggested a role of BNST-projecting vPAG DA neurons in the 
modulation of CRF-dependent moods and affective disorders using the acoustic startle 
behavioral paradigm (38).  The above data urges us to examine dopamine release in the 
BNST by vPAG DA neurons, and the modulation of local neurons follow suit.     
While assessing behavioral influences of the vPAG dopamine neurons via 
DREADD-injections into the vPAG in both TH-cre and wild type animals, we conducted 
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assays to assess anxiety-like behavior, such as open field test, elevated plus maze, 
light/dark box, in addition to a pain perception assay via the Von Frey hyperalgesia test.  
We found no significant difference between TH-cre and wild type groups in anxiety 
assays upon activation of DREADD in vPAG DA neurons via the injection of CNO.  
However, we found significant differences in the Von Frey hyperalgesia assay.  The TH-
cre mice displayed a robust anti-nociception effect comparing to the wild type animals, 
suggesting that the activation of vPAG DA neurons is analgesic.  This is consistent with 
other studies where selective dopamine lesions or dopamine antagonism in the vPAG 
attenuates opioid-induced analgesia (42, 320), and microinjections of DA agonist in the 
vPAG also cause a robust anti-nociception that can be inhibited by antagonists.  
However, we found no significant anxiety-like effects upon activation of the vPAG DA 
neurons.  One possibility to this observation is that the vPAG DA neurons could be 
synapsing onto neurons that dive anxiolysis.  The kinetics of DREADD activation could 
also contribute to this observation where CNO activation of DREADD could be dispersed 
over time, and not sufficient or robust enough to drive anxiety-like behavior.  Taken 
together, we found that vPAG DA activation could potentially modulate the projection 
area, BNST, by increasing excitatory transmission.  In addition, vPAG DA plays an 
important role in the ascending nociceptive control (ANC) pathway, and can produce 
analgesia effects when excited.   
It is currently still unclear how vPAG DA neurons influence negative emotional 
behaviors such as anxiety and depression through the modulation of projection areas.  
Given the prominent role of BNST in stress-related behaviors and our findings that vPAG 
DA neuron activation could release glutamate onto BNST neurons, it is tempting to 
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speculate that vPAG DA actions on this circuit are involved in these processes.  Future 
studies utilizing optogenetics and fast-scan cyclic voltammetry to probe the role of 
dopamine release from specific pathways and cell type-specific modulation will likely 
shed light on this exciting possibility. 
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FIGURES AND TABLES 
 
Figure 4.1:  BNST receives dopamine projections from both the VTA and vPAG, while 
vPAG DA neurons co-expressing vGlut2 project to a sub-region of the dorsal 
BNST.  Injection of the retrograde tracer fluorogold (FG) into the BNST demonstrated 
that tyrosine hydroxylase (TH)-positive cells in the (A) VTA and (B) vPAG project to the 
BNST. Next, we stained for TH in a vGlut2-Ai3 reporter mouse to illustrate that (C) 
dopamine neurons in the vPAG are also (D) vGlut2-positive.  (E) BNST images of 
vGlut2-Ai3 mice revealed that vGlut2-positive neurons terminals populated a sub-region 
of the BNST that highly resembles the oval nucleus. 
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Figure 4.2: GABAergic and dopaminergic cell body distribution in the vPAG.  A 
GAD67-eGFP animal co-stained for TH demonstrated that dopaminergic neurons are 
located ventral and medial to the aqueduct, and GABAergic neurons are situated laterally 
to the aqueduct.  Further, the GABAergic and dopaminergic neurons are distinct from 
one another and do not co-express. 
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Figure 4.3:  Light-evoked action potential in the vPAG DA neurons.  A vGlut2-cre 
mouse was injected with a viral vector of double inverted channelrhodopsin(ChR2)-
mcherry into the vPAG.  Transfected cell bodies in the vPAG that expressed mcherry 
were visualized and recorded from.  Blue light stimulation pulses varying in frequency 
were presented while the vPAG dopamine neurons fired in a time-locked manner at 
corresponding frequencies of 1, 5, 10, 20, and 40Hz. 
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Figure 4.4:  Light-evoked glutamatergic current in the BNST neurons.  A vGlut2-cre 
mouse was injected with a viral vector of double inverted channelrhodopsin(ChR2)-
mcherry into the vPAG.  Transfected vGlut2 terminals projected from the vPAG 
expressed mcherry and could be visualized in the BNST.  Neurons in proximity to 
clusters of mcherry-expressing terminals were recorded from.  Blue light stimulation 
pulses varying in frequency were presented while glutamatergic current were evoked in 
BNST neurons at corresponding frequencies of 1, 5, 10, 20, and 40Hz. 
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Figure 4.5:  Light-evoked GABAergic and glutamatergic currents in the BNST neurons. 
A TH-cre mouse was injected with a viral vector of double inverted 
channelrhodopsin(ChR2)-mcherry into the vPAG.  Transfected TH projections from the 
vPAG expressed mcherry and could be visualized in the BNST.  Neurons in proximity to 
clusters of mcherry-expressing terminals were recorded from.  Blue light stimulation 
pulses were presented and both (A) evoked-GABAergic and (B) evoked-glutamatergic 
currents were observed in BNST neurons. 
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Figure 4.6:  Activation of vPAG TH-positive dopamine neurons produced a robust anti-
nociceptive effect.  TH-cre and wild type animals were injected with viral vectors of 
double inverted Gq-coupled DREADD into the vPAG.  Upon activation of vPAG 
dopamine neurons via the injection of CNO prior to the Von Frey hyperalgesia test, TH-
cre animals displayed a significant decrease in response to the hyperalgesia test than the 
wild type animals. 
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Figure 4.7:  Activation of vPAG TH-positive dopamine neurons had no significant 
effects on open field assay.  Upon activation of vPAG dopamine neurons via the injection 
of CNO prior to the open test, there was no significant differences in A) total distance 
traveled, B) time spent in center, and C) entrance number to center between TH-cre and 
wild type animals.  
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Figure 4.8:  Activation of vPAG TH-positive dopamine neurons had no significant 
effects on elevated plus maze assay.  Upon activation of vPAG dopamine neurons via the 
injection of CNO prior to the open test, there was no significant differences in A) time 
spent in open arms, B) entry number to open arms, C) time spent in closed arms, and D) 
entry number to closed arms between TH-cre and wild type animals.  
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Figure 4.9:  Activation of vPAG TH-positive dopamine neurons had no significant 
effects on light/dark box assay.  Upon activation of vPAG dopamine neurons via the 
injection of CNO prior to the open test, there was no significant differences in A) time 
spent in light compartment, B) entry number to light compartment, C) time spent in dark 
compartment, and D) entry number to dark compartment between TH-cre and wild type 
animals. 
 CHAPTER 5. GENERAL DISCUSSION 
Substance abuse, a global threat to health and productivity, has become an 
increasingly difficult problem to solve, as access to commercially available uncontrolled 
substances and legal prescription drugs are easy to acquire, and many of which are highly 
addictive, putting average families at risk.  The vPAG, a somewhat neglected brain 
region in the research of drug abuse, is ideally positioned to regulate drug-seeking 
behaviors and the negative affects that are so often associated with drug withdrawal.  
Previous chapters provide evidence that link vPAG functions to many negative emotional 
behaviors, as well as demonstrate the role vPAG DA neurons play in the rewarding 
properties of drugs of abuse.  Despite their demonstrated relevance to both emotional 
behaviors and drug abuse, little has been done to characterize vPAG dopamine neurons.  
To better speculate the role of vPAG DA neurons in drugs of abuse and negative affects, 
it is necessary to understand the what, how and where of this cell population: what are the 
differences between vPAG DA neurons and dopamine neurons in other regions? How are 
they modulated by neighboring networks and drugs of abuse? To where do they project 
and how do they influence target areas?  Although the heterogeneity in the vPAG has 
made it difficult to isolate neural systems to examine their synaptic properties the 
modulation of functions, this dissertation utilizes genetic tools and cutting edge 
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techniques that allow us to address cell-type specific and projection-specific functions 
and modulation.   
First, we examined the effects of alcohol in the vPAG DA neurons.  As mentioned 
previously, both acute and chronic alcohol modulate synaptic transmission in VTA 
dopamine neurons; however, the vPAG DA neurons, an extended population of the VTA 
DA neuron group, displayed a surprising resilience to alcohol exposure.  Concentrations 
of alcohol that commonly induce synaptic alterations in other brain regions had no effect 
on vPAG DA inhibitory transmission regardless of the method of administration and 
measurement.  Acute alcohol administration, whether through in vivo i.p. injections or ex 
vivo bath application, had no influence on electrically evoked and spontaneous IPSCs.  
Given that GABA receptors display subunit-dependent sensitivity to alcohol, it is 
possible that GABAergic receptor-composition in the vPAG could be drastically different 
than that in other brain regions, buffering the effects of alcohol in the vPAG. Further 
examination of GABA subunit expression in the vPAG could provide more information 
on the unique resilience to alcohol in this brain region.   
We also observed no difference in synaptic transmission after 2 cycles of alcohol 
exposure.  While other studies have found this paradigm sufficient to induce synaptic 
changes in C57BL/6J mice, the Swiss Webster mice used in these experiments displayed 
no alteration in response to alcohol exposure.  A longer exposure period could be 
required for the Swiss Webster background mice to produce synaptic changes; however, 
we did observe a robust increase in aggressive behavior, contrasting with the generally 
docile demeanor of Swiss Webster mice.  Alcohol-induced aggression has been reported 
across species (230, 231), and interestingly, some of the proposed sites for defensive and 
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aggressive behaviors include the lateral habenula glutamatergic inputs onto the dorsal 
PAG, where raphe serotonergic neurons also innervate (72, 278), as well as the dorsal 
PAG projections to the hypothalamus/thalamus.  Together, this evidence suggests a 
potential role of vPAG mediating alcohol-induced aggression for future investigation. 
Having investigated the effects of alcohol on vPAG DA neurons, we next 
examined the modulation of these neurons by kappa opioid receptors, which mediate both 
drinking behaviors and negative emotional behaviors.  We demonstrated that KOR-
activation induced a significant decrease in GABA-mediated inhibitory inputs (mIPSC), 
and that this attenuation in transmission is mediated through a presynaptic KOR 
mechanism.  Through a series of experiments to eliminate possible signaling transduction 
pathways, we concluded that the βγ subunit of the GPCR mediated the observed 
presynaptic KOR-inhibition, possibly through a change in the release machinery.  
Although our data clearly demonstrated that KOR-activation attenuates inhibitory 
transmission onto vPAG DA neurons, the ways in which KOR activity can influence 
excitatory transmission and overall excitability remain unknown.  However, with such a 
significant decrease in inhibitory input, it is likely that vPAG DA neurons could be 
disinhibited, subsequently increasing in firing rate and signaling in projection regions.  
Given that vPAG DA neurons project to regions mediating negative affect such as stress 
and anxiety and that KOR actions mediate dysphoria, it is possible that KOR-
disinhibition   of vPAG DA neurons enhances target region signaling, increasing negative 
emotions.  While mu-opioid receptor (MOR)-activation is generally known to produce 
euphoric effects (321), it would be interesting to probe this hypothesis and examine MOR 
effects on the vPAG DA neurons for possible differential modulation. 
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This dissertation made one of the first attempts to characterize the membrane 
properties of vPAG dopamine neurons.  We demonstrated that although the vPAG DA 
neurons and the well-studied VTA DA neurons share a common projection region, the 
stress center BNST, they display distinct differences in membrane properties.  This 
finding emphasizes the possibility that vPAG and VTA dopamine neurons could have 
distinct synaptic properties, corresponding with our finding that vPAG DA neuron IPSCS 
are resilient to alcohol exposure while other studies show VTA DA neurons susceptible.  
Using retrograde tracer injection into the BNST, we demonstrated that both the vPAG 
and VTA project to the BNST, however, their respective distribution is unknown. Given 
that dopamine neurons in these two regions are different in membrane properties and 
response to alcohol, it is highly possible that they regulate activities in the BNST in a 
diverging manner.   
Our studies also show that vPAG DA neurons co-express vGlut2, and via 
optogenetic approach, light-stimulation of TH terminals originating from the vPAG can 
evoke glutamatergic currents in the BNST, supporting the hypothesis that vPAG DA 
neurons can modulate the projected region.  The TH-cre mice injected with a cre-
inducible eYFP illustrated a dense and localized glutamatergic projection to the oval 
nucleus of the BNST; however, projection-specificity is undefined as some VTA DA 
neurons also co-express glutamate.  The projection-specific distribution in the BNST 
could be addressed via the injections of AAV-DIO- vectors expressing different 
fluorophores into the VTA and vPAG of TH-cre mice, resulting in the expression of 
different fluorophores, representing two distinct dopamine populations.  Similar approach 
could be taken by injecting two AAV-DIO-ChR2 vectors that are activated by different 
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spectral wavelengths.  Via this approach, we could distinctly activate one projection 
verses another, while examining BNST synaptic transmission during light activation.  
This would provide us with the necessary information in understanding how dopamine 
neuron projections to the BNST from two distinct regions modulate target region activity. 
Another method to acquire both cell type- and projection-specific activation is the 
Flp-FRT recombination, analogous to the Cre-lox recombination.  In the TH-cre animals, 
the retrograde cre-inducible Flp vector (HSV-DIO-Flp) is injected into the projection site 
(BNST) to be taken up by the terminals of cre-expressing cell types, while the cre- and 
Flp-inducible FRT-ChR2-(fluorophore) is injected into the cell body region (vPAG).  
Because the injected Flp is cre-inducible, the recombination of Flp-FRT can only occur in 
cre-expressing cells, only TH-positive neurons will be expressing the light-activated 
ChR2 for manipulation.  The few different viral vectors mentioned above are all suitable 
to address cell type- and projection-specificity both ex vivo and in vivo.  Although our in 
vivo Gq-DREADD data demonstrated a robust vPAG DA neuron-activation-induced 
anti-nociception, this experiment was activating all of vPAG DA projections.  Our data 
suggested that both alcohol and KOR activation have the potential of increasing vPAG 
DA neuron activities.  In addition, both alcohol withdrawal and KOR activation have 
been shown to increase negative emotions such as stress and anxiety.  Thus, it is 
important to investigate the meaning of vPAG DA neuron activation in terms of 
addiction-related behaviors and associated negative affect.  To address the role vPAG DA 
activity plays in mediating stress and anxiety, one of optogenetic approaches mentioned 
above can be applied in vivo in combination with an array of behavioral assays.   
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This work characterized vPAG DA neurons and investigated their modulation by 
alcohol and KOR activity.  Acute alcohol increased excitatory glutamatergic inputs and 
overall activity of the vPAG DA neurons, but had no effect on inhibitory GABAergic 
inputs.  In addition, KOR activation attenuated GABAergic transmission onto vPAG DA 
neurons via presynaptic GPCR βγ subunit signaling.  In support of the original 
hypothesis, evidence showed that vPAG DA neurons co-express glutamtate, and project 
to the stress center, BNST.  Activation of this vPAG DA input to the BNST produced 
glutamatergic currents, suggesting synaptic transmission modulation by the vPAG.  This 
work indicated a strong potential of vPAG DA neurons to directly modulate negative 
affective disorders that are often associated with alcohol and drug abuse, rendering 
treatment ineffective or short-lived.  While further investigation is necessary, our results 
provided critical information on the mechanisms and modulation of vPAG DA neurons 
that could assist in the development of treatment for both drug abuse and emotional 
disorders. 
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